12-2016

Environmental Signaling through the Target of Rapamycin Complex 1 (TORC1) and the Regulation of Epigenetic Mechanisms

Jason J. Workman
University of Tennessee Health Science Center

Follow this and additional works at: http://dc.uthsc.edu/dissertations
Part of the Medical Biochemistry Commons, Medical Cell Biology Commons, and the Medical Genetics Commons

Recommended Citation
Environmental Signaling through the Target of Rapamycin Complex 1 (TORC1) and the Regulation of Epigenetic Mechanisms

Document Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Program
Biomedical Sciences

Track
Cancer and Developmental Biology

Research Advisor
Ronald N. Laribee

Committee
Mondira Kundu Janet F. Partridge Lawrence M. Pfeffer Zhaohui Wu

ORCID
http://orcid.org/0000-0002-9071-5207

DOI
10.21007/etd.cghs.2016.0415

This dissertation is available at UTHSC Digital Commons: http://dc.uthsc.edu/dissertations/408
Environmental Signaling through the Target of Rapamycin Complex 1 (TORC1) and the Regulation of Epigenetic Mechanisms

A Dissertation
Presented for
The Graduate Studies Council
The University of Tennessee
Health Science Center

In Partial Fulfillment
Of the Requirements for the Degree of
Doctor of Philosophy
From The University of Tennessee

By
Jason J. Workman
December 2016
DEDICATION

This work is dedicated to my loving wife, for continually reminding me what I’m capable of, and for giving me something to look forward to at the end of the day.
ACKNOWLEDGEMENTS

We would like to acknowledge the people who made this work, and my matriculation through The University of Tennessee Health Science Center, possible.

First, I want to thank my fantastic Dissertation Committee, Dr. Larry Pfeffer, Dr. Sunny Wu, Dr. Mondira Kundu and Dr. Janet Partridge, for their thoughtful reading of this dissertation and guidance throughout the process. Next, my track director Dr. Tiffany Seagroves and program director Dr. Ren Ostrom, for helping me to stay on top of all the courses and paperwork necessary to complete the process. Additionally, I have to mention the great group of people in the Graduate Health Sciences and Pathology offices, particularly Ms. Barbara Frederick, Ms. Felicia Washington, Ms. Elizabeth Webb, and CGHS dean Dr. Don Thomason.

We also would like to recognize Dr. Dan Klionsky (University of Michigan) for providing us with the Tap42 temperature sensitive plasmids, and Dr. Mary Miller (Rhodes College) for assisting with tetrads dissections.

Lastly, I want to thank my colleagues in the Laribee Laboratory. Dr. Hongfeng Chen for providing me with great ideas and feedback throughout the process (and for teaching me a little Chinese), and my mentor Dr. Nick Laribee, who has my sincere gratitude for taking me in as his first student trainee and providing an environment that allowed me to explore my potential and become the scientist that I am today. My work in the Laribee Laboratory was supported by funding from the American Heart Association and the National Institute of Health.
ABSTRACT

The gene expression profile of a eukaryotic cell is responsive to a variety of extracellular stimuli, including nutrient availability, which allows cells to toggle between anabolism and catabolism based on the favorability of their environment. Much of this information is relayed through signaling complexes, such as the target of rapamycin complex 1 (TORC1), to downstream chromatin modifying enzymes. These enzymes impact the gene regulatory process through altered histone post-translation modifications, changes in chromatin structure, and docking of chromatin regulatory complexes. Yet, despite preliminary studies suggesting that TORC1 affects epigenetic mechanisms, including histone H3 lysine 56 acetylation (H3K56ac), almost nothing is known about how the complex functions in this regard. In this report, we demonstrate that inhibition of TORC1 results in a site-specific reduction in acetylation on N-terminal residues of both histone H3 and H4. This effect is dependent on sirtuin histone deacetylases (HDACs), as inactivation of these enzymes, specifically Hst4, rescues the acetylation defect. We also find that this sirtuin-mediated deacetylation response requires a functional protein phosphatase 6 complex (PP6). PP6 is under direct negative regulation of TORC1, and relief of this inhibition initiates a rapid cytoplasmic to nuclear redistribution of Hst4 which correlates temporally with our observed loss of histone acetylation. The nuclear accumulation of Hst4 precedes an increase in Hst4 protein levels that occurs due to a reduction in Hst4 turnover. Notably, deletion of a subset of sirtuins (hst3Δ or hst4Δ) rescued the sensitivity of a non-essential TORC1 mutant (tco89Δ) to an array of TORC1 inhibitors. This result suggests the link between TORC1 and acetylation may play an essential role in cell cycle regulation and the DNA damage response. We further evaluated whether these TORC1-mediated acetylation marks contribute to the chromatin association of high mobility group proteins (HMGs). And while TORC1-dependent displacement of the HMGs coincides with vacuolar acidification, hyperactivation of TORC1, and significant cell death, it appears to occur independently of TORC1’s regulation of Hst4. We conclude by investigating mitochondrial function in a tco89Δ mutant and mapping the functional domains of Tco89 necessary to sustain TORC1 activity and respond to extracellular stress.
TABLE OF CONTENTS

CHAPTER 1. INTRODUCTION .....................................................................................1
Histone Proteins and Chromatin Organization .........................................................1
The Epigenome ...........................................................................................................1
Advantages of the S. cerevisiae Model System for Epigenetic Studies ....................5
Coordination of Nutrient Availability, Anabolism and Cellular Aging ....................5
Identification of the Target of Rapamycin Genes ....................................................5
The TORC1 Complex .................................................................................................6
Downstream Effectors of TORC1 ..............................................................................7
  Sch9 kinase ..............................................................................................................7
  The PP6 phosphatase complex and Tap42 ............................................................9
Amino Acid Signaling through TORC1 .................................................................13
  Yeast ....................................................................................................................13
  Mammals .............................................................................................................13
TORC1’s Nuclear Functions .....................................................................................14
  Effects on ribosomal DNA transcription ............................................................14
  TORC1, sirtuins, and the epigenetic modification of histones ...............................15
High-Mobility Group Proteins: “The Architectural Transcription Factors” ..........19
Tor Dysfunction and Age-Related Pathologies ....................................................21

CHAPTER 2. MATERIALS AND METHODOLOGY ...............................................23
Yeast Strains, Plasmids, and Culture Conditions .....................................................23
Antibodies and Stains ...............................................................................................23
Western Blotting and Statistical Analysis ...............................................................24
Spotting Assays .......................................................................................................24
RT-qPCR ..................................................................................................................24
Indirect Immunofluorescence Confocal Microscopy ..............................................25
Direct Immunofluorescence Confocal Microscopy ...............................................25
Image Analysis in Zen 2 Blue ..................................................................................25
Sirtuin Turnover/Half-Life Analysis .......................................................................26
Apoptosis, Necrosis, DHE and CFDA Assays ........................................................26
Scoring for Tco89 Fragment Phenotypes ...............................................................27

CHAPTER 3. TORC1 FUNCTION MAINTAINS HISTONE ACETYLATION BY OPPOSING THE SIT4-DEPENDENT NUCLEAR ACCUMULATION OF SIRTUINS .........................................................28
TORC1 Mediates Site-Specific Histone H3 and H4 Acetylation in Response to Environmental Stress, Particularly Glutamine Starvation ........................................28
TORC1 Signals through the Tap42-Sit4 PP6 Phosphatase Complex to Regulate Site-Specific Histone Acetylation Globally ......................................................31
TORC1-Responsive Histone Acetylation Is Specifically Regulated by the Sirtuin Histone Deacetylases .........................................................................................37
Sit4 Activation Downstream of TORC1 Inhibition Promotes Hst4 Stabilization .........40
Hst4 Nuclear Accumulation Occurs Rapidly as a Consequence of TORC1 Inhibition and Sit4 Activation, and Precedes the Increase in Hst4 Stability ........................................44
TORC1-Dependent Histone Acetylation Does Not Impact RP Gene Transcription, But Does Contribute to a Subset of TORC1-Regulated Biological Functions ..........48

CHAPTER 4. HMG DISPLACEMENT OCCURS INDEPENDENTLY OF TORC1-MEDIATED HISTONE ACETYLATION TO PROMOTE A NOVEL, STRESS-RESPONSIVE CELL DEATH .................................................................53
H3K37A Mutation Correlates with HMGB Nuclear Delocalization and Is Sufficient to Change Rapamycin from a Cytostatic to a Cytotoxic Agent ..........................53
Aberrant HMGB Expression and Localization Result in Vacuolar Acidification and Apoptotic and Necrotic Cell Death through a Novel Death Pathway ................56
H3K37A Mutants Display Increased TORC1 Activity, Which Correlates with Displacement of HMGBs and Can Be Reversed by HMGB Deletion ........................58

CHAPTER 5. INVESTIGATING THE ROLE OF TCO89 IN TORC1 ..........................62
Identification of the Domain Necessary for Tco89-Dependent TORC1 Functions .....62
The Observed Cell Cycle Arrest in tco89Δ Upon TORC1 Limitation Is Not Attributable to Dysregulation of Reactive Oxygen Production .................................65

CHAPTER 6. DISCUSSION AND FUTURE DIRECTIONS ....................................68
TORC1 and Histone Acetylation ..........................................................................68
The PP6 Phosphatase Complex and the TORC1-Dependent “Acetylome” ........70
Spt7 ....................................................................................................................73
Ifh1 ......................................................................................................................73
Mitochondrial proteins .........................................................................................74
TORC1-Dependent Histone Acetylation and Anabolic Gene Transcription .......75
Interplay between Histone Acetylation and Sensitivity to TORC1 Inhibition ....76
Epigenetic Dysfunction and Cellular Transformation .......................................77
TORC1-Dependent Acetylation Does Not Contribute to HMGB Chromatin Binding ..................................................................................................................78
Cells with Aberrant HMG Localization Undergo Massive Cell Death Characterized by Vacuolar Dysfunction and Hyperactive TORC1 .................................80
Mapping the Functional Domains of Tco89 .......................................................81
Closing Remarks .................................................................................................83

LIST OF REFERENCES .........................................................................................85
APPENDIX A. SUPPLEMENTAL TABLES .............................................................106
APPENDIX B. SUPPLEMENTAL FIGURES .........................................................111
VITA .....................................................................................................................119
**LIST OF TABLES**

Table 1-1. Summary of sirtuin histone deacetylase localization and substrate specificity in yeast. .................................................................................................................................16

Table 1-2. Summary of sirtuin histone deacetylase localization and specificity in mammals. .................................................................................................................................18

Table A-1. List of strains used in this study.................................................................................................................................106

Table A-2. List of plasmids used in the study.................................................................................................................................110
LIST OF FIGURES

Figure 1-1. Cartoon representation of chromatin packaging. ............................................2
Figure 1-2. Schematic of the nucleosome..........................................................................3
Figure 1-3. Transcriptional availability of DNA is mediated by the epigenetic modifications of histones. .................................................................4
Figure 1-4. Downstream effectors of the TORC1 signaling pathway and their functions in S. cerevisiae .................................................................8
Figure 1-5. The activation of Tap42-associated phosphatases in response to TORC1 inhibition. ...........................................................................12
Figure 3-1. TORC1 signaling coordinates site-specific lysine acetylation on a subset of histone H3 and H4 N-terminal residues. ..................................................29
Figure 3-2. TORC1-dependent histone acetylation is responsive to nitrogen, but not carbon, limitation. ........................................................................30
Figure 3-3. Regulation of histone acetylation downstream of TORC1 occurs independently of the Sch9 kinase. ...............................................................32
Figure 3-4. TORC1-responsive histone acetylation is regulated in a Tap42-dependent fashion.................................................................33
Figure 3-5. Sit4-catalyzed PP6 complex activity is required for TORC1-responsive histone acetylation.................................................................35
Figure 3-6. Regulatory subunits of the PP6 phosphatase complex display overlapping function in relation to TORC1-responsive histone acetylation. ........................................................................36
Figure 3-7. Sit4-dependent, nitrogen-responsive chromatin modifications are separable from the canonical nitrogen catabolite response (NCR) pathway. .............................................................................................................36
Figure 3-8. TORC1-PP6 catalyzed histone H3/H4 deacetylation is promoted by the NAD⁺-dependent sirtuin family of histone deacetylases. ........................................38
Figure 3-9. Class I and II histone deacetylases are not involved in the observed TORC1-PP6 hypoacetylation response .................................................38
Figure 3-10. TORC1-responsive histone acetylation is modulated by a subset of sirtuin histone deacetylases in a site-specific fashion. ........................................39
Figure 3-11. Reduced TORC1 signaling activates PP6 to increase Hst4 protein levels ...41

Figure 3-12. PP6-dependent changes in Hst4 protein levels are not due to increased HST4 mRNA expression. ........................................................................................................42

Figure 3-13. PP6 activation downstream of TORC1 inhibition initiates a reciprocal shift in Hst3/Hst4 stability. .................................................................................43

Figure 3-14. Hst3 and Hst4 phosphorylation state is independent of TORC1 function. ...45

Figure 3-15. TORC1 suppression drives Hst4 nuclear accumulation in a Sit4-dependent fashion. ............................................................................................................46

Figure 3-16. Hst4 nuclear accumulation occurs rapidly as a consequence of TORC1 inhibition and precedes the increase in Hst4 protein stability. .........................47

Figure 3-17. Global loss of TORC1-responsive acetylation marks does not correlate with a change in expression of a subset of ribosomal protein genes. ..........49

Figure 3-18. TORC1-PP6 regulated histone acetylation is functionally significant for a subset of TORC1-dependent processes. ...............................................................50

Figure 3-19. Hst4 contributes to cellular ROS levels independently of TORC1. ........52

Figure 4-1. The H3K37A mutation correlates with HMGB nuclear delocalization and converts rapamycin from a cytostatic to cytotoxic agent. .........................54

Figure 4-2. Partial restoration of TORC1 responsive histone H3/H4 acetylation does not reverse Nhp6A nuclear delocalization or cell death. .............................55

Figure 4-3. Aberrant HMGB localization results in vacuolar acidification. ..........57

Figure 4-4. Buffering intracellular pH is sufficient to partially reverse the rapamycin sensitivity of an H3K37A mutant.................................................................59

Figure 4-5. H3K37A mutants display increased TORC1 activity that depends on the presence of specific HMGB factors. .................................................................60

Figure 5-1. Construction of Tco89 mutant expression vectors...............................63

Figure 5-2. Identification of the functional domain necessary for Tco89-dependent TORC1 functions. .................................................................................................64

Figure 5-3. Loss of Tco89 results in adaptive ROS response similar to that observed in tor1Δ. .............................................................................................................66

Figure 6-1. Proposed mechanism. ........................................................................72
Figure B-1. TORC1 inhibition over a range of rapamycin treatment conditions compared to a \textit{tco89A} mutant.................................................................111

Figure B-2. Control experiments for Sch9^{2D3E} expression vectors. .............................112

Figure B-3. Sirtuin relocalization in response to TORC1 inhibition. .............................113

Figure B-4. Disruption of TORC1-responsive histone acetylation has no effect on H3K37A sensitivity to rapamycin.................................................................117

Figure B-5. Galactose-inducible HMGB expression vectors promote aberrant protein levels and distribution of Hmo1 and Nhp6A even prior to addition of galactose. ................................................................................................................118
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>AsO₃</td>
<td>Arsenic trioxide</td>
</tr>
<tr>
<td>CFDA</td>
<td>5(6)-carboxyfluorescein diacetate</td>
</tr>
<tr>
<td>ChIP</td>
<td>Chromatin immunoprecipitation</td>
</tr>
<tr>
<td>ChIP-seq</td>
<td>Chromatin immunoprecipitation sequencing</td>
</tr>
<tr>
<td>CR</td>
<td>Caloric restriction</td>
</tr>
<tr>
<td>DHE</td>
<td>Dihydroethidium</td>
</tr>
<tr>
<td>FITC</td>
<td>Fluorescein isothiocyanate</td>
</tr>
<tr>
<td>FKBp</td>
<td>FK506-binding protein</td>
</tr>
<tr>
<td>GAP</td>
<td>GTPase-activating protein</td>
</tr>
<tr>
<td>GEF</td>
<td>Guanine exchange factor</td>
</tr>
<tr>
<td>HATs</td>
<td>Histone acetyltransferases</td>
</tr>
<tr>
<td>HDACs</td>
<td>Histone deacetylases</td>
</tr>
<tr>
<td>HMG</td>
<td>High-mobility group protein</td>
</tr>
<tr>
<td>HMG (A/B/N)</td>
<td>High-mobility group protein A/B/N family member</td>
</tr>
<tr>
<td>HMGB1</td>
<td>High-mobility group box 1 protein</td>
</tr>
<tr>
<td>IB</td>
<td>Immunoblot</td>
</tr>
<tr>
<td>MCRS1</td>
<td>Microspherule protein 1</td>
</tr>
<tr>
<td>MES</td>
<td>2-(N-morpholino) ethanesulfonic acid</td>
</tr>
<tr>
<td>MMS</td>
<td>Methyl methanesulfonate</td>
</tr>
<tr>
<td>MSX</td>
<td>L-methionine sulfoximine</td>
</tr>
<tr>
<td>mTor</td>
<td>Mechanistic target of rapamycin (in reference to the kinase)</td>
</tr>
<tr>
<td>mTORC1</td>
<td>Mechanistic target of rapamycin complex 1</td>
</tr>
<tr>
<td>Acronym</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>NAD+/NADH</td>
<td>Nicotinamide adenine dinucleotide</td>
</tr>
<tr>
<td>NCR</td>
<td>Nitrogen catabolite repression (response)</td>
</tr>
<tr>
<td>PGC-1α</td>
<td>Peroxisome proliferator-activated receptor-gamma coactivator-1 α</td>
</tr>
<tr>
<td>PHO pathway</td>
<td>Phosphate-responsive signaling pathway</td>
</tr>
<tr>
<td>PI</td>
<td>Propidium iodide</td>
</tr>
<tr>
<td>PI3K</td>
<td>Phosphoinositide 3-kinase</td>
</tr>
<tr>
<td>Pkh1/2</td>
<td>Pkb-activating kinase homolog 1/2</td>
</tr>
<tr>
<td>PP2A</td>
<td>Protein phosphatase 2A complex</td>
</tr>
<tr>
<td>PP4</td>
<td>Protein phosphatase 4 complex</td>
</tr>
<tr>
<td>PP6</td>
<td>Protein phosphatase 6 complex</td>
</tr>
<tr>
<td>PPG1</td>
<td>Protein phosphatase involved in glycogen accumulation</td>
</tr>
<tr>
<td>PPP6C</td>
<td>Protein phosphatase 6, catalytic subunit (mammalian)</td>
</tr>
<tr>
<td>PPP6R1/2/3</td>
<td>Protein phosphatase 6, regulatory subunits 1/2/3 (mammalian)</td>
</tr>
<tr>
<td>PTEN</td>
<td>Phosphatase and tensin homolog</td>
</tr>
<tr>
<td>Rab1A</td>
<td>Ras-related protein 1A</td>
</tr>
<tr>
<td>rDNA</td>
<td>Ribosomal DNA</td>
</tr>
<tr>
<td>RNA-seq</td>
<td>RNA sequencing</td>
</tr>
<tr>
<td>RNAPI/II/III</td>
<td>RNA polymerase I/II/III</td>
</tr>
<tr>
<td>ROS</td>
<td>Reactive oxygen species</td>
</tr>
<tr>
<td>RP</td>
<td>Ribosomal protein (genes)</td>
</tr>
<tr>
<td>rRNA</td>
<td>Ribosomal RNA</td>
</tr>
<tr>
<td>RSC</td>
<td>Remodels structure of chromatin complex</td>
</tr>
<tr>
<td>S6K1</td>
<td>S6-kinase 1</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>SAGA</td>
<td>Spt-Ada-Gen5-acetyl-transferase</td>
</tr>
<tr>
<td>SASP</td>
<td>Senescence-associated secretory phenotype</td>
</tr>
<tr>
<td>SCF</td>
<td>Skp, Cullin, F-box containing complex</td>
</tr>
<tr>
<td>SD</td>
<td>Standard deviation</td>
</tr>
<tr>
<td>SEACIT</td>
<td>SEAC subcomplex inhibiting TORC1 signaling</td>
</tr>
<tr>
<td>SIRT1-7</td>
<td>Silent mating type information regulation 2 homolog 1/2/3/4/5/6/7</td>
</tr>
<tr>
<td>SOD1</td>
<td>Superoxide dismutase 1</td>
</tr>
<tr>
<td>SWI/SNF</td>
<td>Switch/Sucrose non-fermentable</td>
</tr>
<tr>
<td>TCFI</td>
<td>Total cellular fluorescence intensity</td>
</tr>
<tr>
<td>TNFI</td>
<td>Total nuclear fluorescence intensity</td>
</tr>
<tr>
<td>TIF-IA</td>
<td>Transcription initiation factor 1A</td>
</tr>
<tr>
<td>Tor1/2</td>
<td>Target of rapamycin 1 or 2 (in reference to the kinases)</td>
</tr>
<tr>
<td>TORC1/2</td>
<td>Target of rapamycin complex 1/2</td>
</tr>
<tr>
<td>TSC</td>
<td>Tuberous sclerosis complex</td>
</tr>
<tr>
<td>v-ATPase</td>
<td>Vacuolar H+-ATPase</td>
</tr>
<tr>
<td>WCEs</td>
<td>Whole cell extracts</td>
</tr>
<tr>
<td>YEATS</td>
<td>Yaf9, ENL, AF9, Taf14, Sas5 (in reference to the domain)</td>
</tr>
<tr>
<td>Ypk3</td>
<td>Yeast protein kinase 3</td>
</tr>
</tbody>
</table>
CHAPTER 1. INTRODUCTION

Histone Proteins and Chromatin Organization

The histone family of DNA packaging proteins is comprised of four isoforms: H2A, H2B, H3 and H4. Each histone consists of a globular core and a pair of N- and C-terminal tails. All of the core histones exist as heterodimers of H2A/H2B or H3/H4, and assembly of four of these heterodimers (two of each) results in formation of an octameric structure collectively known as the nucleosome [1, 2]. Approximately 146 base pairs of DNA are wound around each nucleosome, resulting in the “beads on a string” structure, noted initially in early electron microscopy analyses of intact chromatin [3]. From there, interactions between the nucleosomes themselves produce a more compacted form of chromatin known as the 30 nm fiber. Additional higher order folding and packaging condenses the 30 nm fiber even further to ultimately form chromosomes (Figure 1-1).

The Epigenome

The epigenome consists of a heritable set of highly complex histone post-translation modifications, including acetylation, methylation, phosphorylation and ubiquitination, which essentially establish a secondary layer of genetic information that is stored above the chromatin. These epigenetic moieties occur predominantly on the N-terminal tails of the histones (Figure 1-2), where they function to coordinate a multitude of chromatin-based processes; most notably, enabling changes to an organism’s phenotype through adjustments in gene expression rather than alterations to the genotype. Methylation of lysines and arginines on the histone tails has a very context specific effect on transcription, which is most often coordinated through mediating the association of methyl-binding proteins (i.e. Tudor domains, MBT domains, PHD domains, chromodomains, and WD proteins) [4-11]. On the other hand, acetylation status of these residues impacts the availability of the histone’s positively charged amino groups to bind to the negatively charged DNA backbone. Specifically, increased acetylation results in a more open and transcriptionally accessible chromatin state, while reduction in these marks promotes a more heterochromatic and transcriptionally occlusive environment (Figure 1-3). Intriguingly, histone acetylation at the ribosomal protein (RP) genes and the ribosomal DNA (rDNA) has been shown to be responsive to signaling through nutrient sensing complexes [12, 13]. This suggests that epigenetic mechanisms could coordinate changes in gene expression in response to environmental nutrient availability. Despite a recent swell of scientific and mainstream interest, there are some who still believe the importance of the histone code and transgenerational epigenetic inheritance has been overstated [14-19].
Figure 1-1. Cartoon representation of chromatin packaging.
DNA is spooled around the nucleosomes to form a loosely condensed, 11 nm fiber, sometimes referred to as the “beads on a string” configuration. Nucleosomal interactions drive additional levels of chromatin packaging, ultimately leading to the formation of chromosomal DNA. See text for more details. Reprinted with permission [20]. DNA Packaging - Shmoop Biology. 2008 [cited 2016 May 11]; Available from: http://www.shmoop.com/dna/dna-packaging.html.
Figure 1-2. Schematic of the nucleosome.
The nucleosome is a histone octamer complex which consists of two heterodimers of both H2A/H2B and H3/H4. The most topical post-translation modifications on the N-terminal tails of each histone are denoted.
Figure 1-3. Transcriptional availability of DNA is mediated by the epigenetic modifications of histones.
Cartoon representation of the dynamic effects acetylation and methylation can have on chromatin packaging, and subsequently, the accessibility of particular regions of DNA for efficient gene transcription. Reprinted with permission [20]. DNA Packaging - Shmoop Biology. 2008 [cited 2016 May 11]; Available from: http://www.shmoop.com/dna/dna-packaging.html.
Advantages of the *S. cerevisiae* Model System for Epigenetic Studies

The study of chromatin, particularly at single nucleosome resolution, proves very challenging in most models or cell lines due to the multicopy nature of the core histone genes. As an example, human cells have 15 copies of the H3 gene, encoding canonical H3 and two additional H3 sequence variants [21, 22]. This high level of redundancy makes probing the specific chromatin contributions of individual histone amino acid residues incredibly difficult. However, due to the evolutionary conservation of the core histones, and because the budding yeast genome encodes only two copies of canonical H3 and H4, *S. cerevisiae* has become an essential model organism for conducting cutting-edge, mechanism-based experiments that are highly translatable. Indeed, our current knowledge of functional genomics, histone dynamics and epigenetic modifications was built on work conducted in budding yeast [23].

Coordination of Nutrient Availability, Anabolism and Cellular Aging

It is critical for all eukaryotic organisms to be able to rapidly adjust their growth and proliferative profiles to account for changing extracellular conditions or intracellular deficits. This principle is most critical as it relates to active cell division, as an inability to coordinate mitosis with nutrient and energy states may prevent sufficient biomass accumulation and have adverse downstream consequences on cell viability [24-27]. In response to these pressures, cells have developed highly conserved nutrient sensing complexes, such as the target of rapamycin complex 1 (TORC1), which couples extracellular nutrient signals with the appropriate intracellular response [28]. Aberrant flux through these sensing pathways contributes to a number of age-related diseases, including diabetes, cancer and cardiovascular disease [29].

Identification of the Target of Rapamycin Genes

The discovery of target of rapamycin (Tor), a protein kinase responsible for mediating cell growth and proliferation in coordination with growth factors and environmental nutrient status, can be traced back to the isolation of rapamycin, a macrolide produced by the Easter Island soil bacterium *Streptomyces hygroscopicus* [30]. Though once a promising antifungal compound, rapamycin’s adverse effects on host T-cell proliferation has led to its present day use as an immunosuppressant and anti-cancer agent (as reviewed by Benjamin)[31]. The rapamycin-dependent effects on T-cell proliferation require the FK506-binding protein (FKBP), a binding partner now known to bridge the association of rapamycin and the FKBP-rapamycin binding domain of Tor [32-34].

The proliferation defect first identified in rapamycin treated T-cells is also observed in the budding yeast *Saccharomyces cerevisiae*, and in both instances, deficiencies are attributable to an early G1 cell-cycle arrest [35]. Genome sequencing of spontaneously rapamycin resistant yeast mutants identified the two genes responsible for
mediating the rapamycin phenotype, and they were aptly named target of rapamycin 1 and 2 (TOR1 and TOR2) [35]. These genes encode a unique pair of PI3-like serine/threonine kinases. Subsequently, an orthologous kinase was discovered in higher order organisms, termed mechanistic TOR (mTor), and since then, Tor kinases have been reported to be conserved across all eukaryotes [36-38]. Characterization of Tor kinase substrates has proven difficult due to the lack of a true consensus sequence, though a few are known and will be discussed below. For clarity and simplicity, nomenclature for the yeast Tor pathway will be used from herein unless otherwise noted.

The TORC1 Complex

The Tor kinases are incorporated into one of two signaling complexes: target of rapamycin complex 1 or 2 (TORC1/2) [39-41]. In metazoans, these complexes are known as mechanistic TORC1/2 (mTORC1/2). There are considerable structural and functional differences between TORC1 and TORC2, the most relevant being that TORC1 is sensitive to environmental stimuli and rapamycin-dependent inhibition while TORC2 is not. Because the overarching interest of our lab is in environmentally regulated epigenetic processes, TORC1 will be our focus for the remainder of this work.

TORC1 consists of the Tor1/2 kinase, Lst8, Kog1, and Tco89 [42]. Lst8 and the Tor2 kinase can be found in both TORC1 and TORC2, but Tor1, Kog1 and Tco89 appear to be TORC1-specific [43]. Accordingly, temperature sensitive mutants of Kog1 (essential), or tco89Δ mutants (non-essential), sensitize cells to direct TORC1 inhibition [43, 44]. Electron microscopy studies have characterized the association between the C-terminal WD40 domain of Kog1 and the N-terminal HEAT repeats of the Tor kinases [45]. Kog1 and its mammalian ortholog, Raptor, contribute to TORC1 function by facilitating a series of interactions, including between the kinase and its substrates [46, 47], and between TORC1 and the vacuole (discussed in detail below) [48, 49]. Further, when nutrients are limiting, the Rho1 GTPase associates with Kog1, resulting in inhibition of TORC1 [50]. Recently, it was reported that TORC1-bound Kog1 is more stable than free Kog1, suggesting association with the complex may also serve to stabilize Kog1 [51].

By comparison, little is known about Tco89. It is currently believed to be a yeast-specific component of TORC1, and homologs have been identified in S. pombe and C. albicans [52, 53]. The existence of a mammalian Tco89 seems likely however, given the considerable conservation of the TORC1 axis. tco89Δ cells have abnormal cellular physiology and budding patterns, as well as dramatically increased sensitivity to stress; including heat, caffeine, MMS, rapamycin and salt [52, 54-60]. tco89Δ mutants phenotypically resemble vacuole mutants (ego1Δ, ego3Δ, gtr1Δ and gtr2Δ), as these strains are all acutely sensitive to rapamycin and unable to reengage the cell cycle following TORC1 stress [43, 61] (discussed in detail later). In support of the above, Tco89 has been reported to mediate physical interactions between TORC1 and the vacuole [49]. Tco89 has also been shown to directly associate with Vac8, an armadillo repeat protein which affects vacuolar functions and caffeine resistance [62], and fructose-
1,6-bisphosphate to mediate its vacuolar turnover [63]. Still, the majority of studies that mention \textit{tco89Δ} do so in the context of suppressor screens [64, 65]. Most of these screens also identify \textit{tor1Δ}, suggesting that Tco89’s most prominent function involves maintaining TORC1 activity. Interestingly, our group has shown that TORC1-dependent histone acetylation is responsive to \textit{tco89Δ} but not \textit{tor1Δ} [66]. A mammalian ortholog of Tco89 could be an attractive therapeutic target given the dramatic and permanent cell cycle arrest that occurs in its absence when sub-inhibitory doses of rapamycin are administered [43, 49].

**Downstream Effectors of TORC1**

When nutrient status and environmental conditions are favorable, TORC1 actively promotes growth programs and simultaneously suppresses stress responses through coordination of a downstream kinase (Sch9) and a series of Tap42-associated phosphatases (Figure 1-4). Conversely, diminished TORC1 signaling during times of starvation or rapamycin treatment causes cells to enter a quiescent state where anabolic flux is suppressed. Fascinatingly, long-term TORC1 inhibition, and subsequent suppression of anabolism, has been shown to extend lifespan across a number of model systems [67-74]. These rapid and dramatic changes in intracellular processes require a coordinated shift in gene expression, which TORC1 has been shown to regulate at the level of mRNA transcription (via transcription factor localization [75]) and translation (at the initiation step of elongation [76-78]). But how TORC1 regulates gene expression, particularly as it relates to chromatin structure, remains a poorly defined function of the pathway.

Recently, it was demonstrated that TORC1 also signals through the Ypk3 kinase to promote phosphorylation of the ribosomal proteins Rps6a/b, though the mechanism remains unclear [79]. Phosphorylation of S6 serves as a readout for TORC1 activity in eukaryotic cells [80], and it will be used as such in the studies presented herein. For now though, we will focus on the Sch9 kinase and the Tap42 phosphatases as they are the best-characterized effector molecules downstream of yeast TORC1 (Figure 1-4).

**Sch9 kinase**

Sch9 is an AGC protein kinase whose activity is directly promoted by TORC1-dependent phosphorylation [80]. The degree of control TORC1 exerts on Sch9 is evident in the fact that \textit{sch9Δ} cells phenocopy the effects of caloric restriction (CR), including extended lifespan, and behave very similarly to a \textit{tor1Δ} [71, 72, 80, 81]. It is important to note that there is also evidence that Sch9 and TORC1 may function synergistically, rather than redundantly, in sensing environmental stressors [82]. This concept is supported by the fact that phosphorylation of the Sch9 activation loop may occur independently of TORC1 via the Pkh1/2 kinases, possibly tying Sch9 into sphingolipid homeostasis as well as to classical TORC1 stimuli [83-85].
Figure 1-4. Downstream effectors of the TORC1 signaling pathway and their functions in *S. cerevisiae*.
TORC1 effectors include yeast protein kinase 3 (Ypk3), the Sch9 kinase, and the Tap42-associated phosphatases. Cellular processes mediated by each are presented as well. See text for more details.
TORC1-dependent phosphorylation mark on the hydrophobic motif of Sch9 is able to fine-tune the Phkh1/2-initiated activity.

The basic function of Sch9 is to promote proper cell cycle progression, transcription initiation, and translation, while simultaneously suppressing induction of autophagy [80, 86-88]. Under favorable environmental conditions, Sch9 phosphorylates and inhibits the transcriptional repressors Maf1, Dot6, Tod6 and Stb3, ensuring transcription of genes necessary for ribosomal biogenesis [60, 86, 89]. Sch9 activity also feeds into the suppression of autophagy, seemingly in concert with RAS/PKA, via regulation of the Atg1-Atg13-Atg17 kinase complex [88]. Additionally, to promote cell cycle progression, Sch9 targets the ubiquitin conjugating enzyme, Cdc34 [90]. An interesting study from Weisman et al. also ties Sch9 into cell cycle control through a unique vacuolar inheritance mechanism. They demonstrate that if this inheritance fails, the cell cycle arrests at G1 in an Sch9-dependent fashion [91]. Conversely, inhibition of Sch9 during times leads to Gcn2-mediated phosphorylation of the translation factor eIF2a, which inhibits its function and blocks protein synthesis [82]. It was also suggested recently that Sch9 regulation of Maf1 may contribute to CR-induced lifespan extension [92].

The PP6 phosphatase complex and Tap42

The Tap42-associated phosphatases are a family of functionally distinct, modular protein phosphatase complexes, which include PP2A, PP4, PP6 and PPG1 [93-96]. These complexes are best known as regulators of non-preferred nitrogen catabolism and the stress response. For brevity, and because PP6 will be the major focus of our work, it will be the only complex discussed in-depth.

The PP6 phosphatase complex exists as a heterodimer consisting of the ceramide-responsive catalytic subunit, Sit4, and one of four Sit4-associated regulatory proteins (Sap4, Sap155, Sap185, or Sap190) [97]. Sit4 regulates expression of the cyclin genes and is required for the execution of cell cycle START (G1), bud formation, initiation of DNA synthesis, and spindle pole body duplication [98, 99]. Overexpression of the Saps in a temperature sensitive Sit4 mutant can partially reverse the observed growth defects, while a complete ablation of the Saps in an otherwise wild-type cell induces a sit4Δ-like slow growth phenotype and G1 delay [97]. Association of the catalytic and regulatory subunits appears to be cell-cycle dependent and indispensable for Sit4 activity in vivo. And while some speculate that the Saps regulate PP6 substrate specificity, their exact function is currently unknown. There is evidence which suggests that each Sap has a unique and distinct contribution to PP6 function, but there is also data that demonstrates at least moderate functional redundancy exists as well [97, 100, 101]. Interestingly, overexpression of metazoan PP6 regulatory subunits (PP6R2 and PP6R3) in the absence of the Saps restores growth and reverses rapamycin sensitivity, suggesting rather significant evolutionary conservation of this modular phosphatase complex [102].
Sit4 is highly influential in the cellular response to altered nutrient states, particularly to changes in amino acid availability. During starvation, the Gln3, Gat1, and Nil1 transcription factors are dephosphorylated by Sit4, which triggers dissociation from their cytoplasmic anchors and entry into the nucleus [103]. There, these factors drive high level expression of genes encoding permeases and enzymes needed to transport and utilize poor nitrogen sources. At the same time, the Sit4 phosphatase is also known to target the Npr1 kinase, leading to its activation and the subsequent stabilization of the general amino acid permease Gap1 [104]. These effects are known collectively as the Nitrogen Catabolite Repression (NCR) response.

Tap42’s association with its family of phosphatases has a somewhat muddled history. It was initially identified in yeast as a 42kDa protein that specifically associates with the PP2A and PP6 protein phosphatase complexes [105]. Tap42 is now known to associate with all of the other PP2A-like phosphatase complexes, including the aforementioned PPG1 and PP4 [96]. Somewhat surprisingly, there is far less Tap42 in the cell than there are phosphatases, as only about 5-10% of cellular PP2A-like phosphatases are bound to Tap42 [105]. Such stoichiometry could suggest that these phosphatases possess Tap42-independent functions or possibly additional substrates that have yet to be identified. Chen et al. utilized a yeast two-hybrid screen to identify a mammalian protein they dubbed α4, which is also capable of binding the N-terminal portion of these phosphatase complexes [106]. The authors report significant sequence conservation between α4 and Tap42, suggesting the proteins may be homologs.

In the late 1990’s, evidence began accumulating that Tap42 and α4 act as negative regulators of the PP2A-like phosphatases. First, Nanahoshi’s group reported that PP2A-dependent dephosphorylation of eIF-4E binding protein was inhibited by the presence of Tap42 and α4 [107]. Subsequently, Beck and Hall suggested that Tap42 and Sit4 form a complex following Tap42 phosphorylation by TOR, and postulated that this was the inactive form of the phosphatase [75]. They found that when phosphatases were dissociated from Tap42, this was accompanied by a dephosphorylation of many downstream targets, concluding that phosphatase release led to its activation. This idea was supported by Jiang and Broach, who later demonstrated that Tap42 association to Sit4 is indeed rapamycin responsive and dependent on TORC1 phosphorylation of Tap42 [108]. Gene expression profiling identified dynamic expression level changes that mirror the release and disassembly of the Tap42-Sit4 complex [109]. Similarly, the inactivation of Tap42 was shown to severely attenuate the rapamycin-induced expression of genes under control of the Sit4-regulated Gln3 transcription factor [110].

More recently, however, many of the initial claims made about Tap42’s function as a negative regulator, as well as its identity as a homolog to α4, have been questioned. In 2006, it was reported that rather than Tap42 functioning as a negative regulator, it may actually be a positive effector of the phosphatases [111]. The timing of this paradigm-shifting experiment proved to be key as it utilized shorter, more closely spaced time points than the Hall study [75]. The authors demonstrated by fractionation that Tap42-phosphatase complexes exist primarily on membrane structures through association with TORC1. They also showed that the TORC1-associated population of Tap42 is almost
exclusively phosphorylated, while the cytoplasmic pool is not. Importantly, they reported that the TORC1-Tap42-Sit4 association is environmentally sensitive, as rapamycin treatment or nutrient starvation releases the Tap42-phosphatase complex into the cytosol. The cytosolic complex then dissociates further, leaving Tap42 and the free phosphatase. Finally, the authors demonstrated that Tap42 dephosphorylation and complex dissociation occurs long after phosphatase activation. These results ultimately illustrated that the cytoplasmic Tap42-PP6 phosphatase complex is indeed the active form, and that the dissociation of Tap42 from Sit4 is not the trigger for phosphatase activity as was previously believed. Interestingly, the interaction between Tap42 and PP6 is independent of whether the Saps are present [105].

This conclusion has subsequently been supported by other groups that have demonstrated that phosphatase activity, and particularly Sit4 function, depends on the presence of Tap42 [96]. In fact, loss of Tap42 prevents Sit4-dependent stress-response genes from being activated [110]. It has also been reported that overexpression of Tap42 along with these phosphatases leads to a growth inhibition phenotype that is more substantial than is seen with the phosphatases alone [105]. Altogether, these results show that Tap42 is indispensable for PP6 phosphatase activity, and we speculate that like α4 [112], Tap42 may be functioning as a chaperone to protect the integrity of the phosphatase complexes.

To summarize, when conditions are favorable for growth, phosphatases are sequestered at the vacuole due to TORC1 phosphorylation of both Tip41, a cytoplasmic binding partner of Tap42, and Tap42 itself (Figure 1-5A). During the initial stages of nutrient stress (Figure 1-5B), the Rho1 GTPase competitively inhibits the Tap42-Kog1 association at the vacuole, which releases and activates the Tap42-PP6 phosphatase complex [50]. Sit4-dependent dephosphorylation of the stress responsive transcription factors results in their localization to the nucleus, and a corresponding shift in the gene expression patterns of the cell. Later in the starvation response (Figure 1-5C), the TORC1-dependent phosphorylation marks on Tip41 and Tap42 are removed, although the responsible phosphatase remains unclear (some postulate it may actually by a self-regulatory function of Sit4). At this point, Tip41 competes for the binding of Tap42 and promotes Tap42-Sit4-Sap complex disassembly [113]. This inactivating event usually occurs approximately 30 minutes after initial introduction of the stress, though it is unclear whether Sit4 remains associated with the Sap following release from Tap42 (denoted by question mark in Figure 1-5C). Eventually, when the environment permits, an inactive holocomplex of Tap42-Sit4-Sap is reformed at the vacuolar surface through associations with active TORC1. As was mentioned above, only a small amount of the Sit4 in a cell is bound to Tap42, and this is almost exclusively the TOR-responsive fraction. What the remainder of Sit4 is doing in the cell, and how phosphatase molecules are “selected” by Tap42, remains to be seen.
Figure 1-5. The activation of Tap42-associated phosphatases in response to TORC1 inhibition.
Cartoon schematic describing the sequence of events culminating in Tap42-associated phosphatase activation as a cell transitions from a nutrient complete environment (A) to an amino acid deficient one (B and C). Active signaling molecules are indicated in green while inactive complexes are shown in red. The question mark in (C) denotes a point which requires future study. See text for more information.
Amino Acid Signaling through TORC1

In order to sense environmental quality, one of the upstream nutrients TORC1 is particularly sensitive to is nitrogen, typically in the form of free amino acids. The quality of a nitrogen source is defined by its ability to promote glutamine accumulation. These catabolites must fuel the equilibrium reactions which maintain cellular levels of α-ketoglutarate, ammonia, glutamine and glutamate. The mechanism through which TORC1 responds to fluctuations in nitrogen donor quality and amino acid availability is only now being delineated, and yet there is already a striking level of similarity between yeast and mammals, as described below.

Yeast

In yeast, the major amino acid sensing node is the EGO complex, consisting of the structural subunit Ego1, the newly discovered Ego2, a homodimer of Ego3, and the Rag GTPases Gtr1 and Gtr2 [61, 114, 115]. The active conformation of the Rag GTPases includes GTP-bound Gtr1 and GDP-bound Gtr2. When amino acids are not limiting, the guanine nucleotide exchange factor (GEF) activity of Vam6 is activated, which subsequently inhibits the Gtr1-targeted GTPase activating protein (GAP) function of the SEACIT complex [49, 116]. Concurrently, activity of the recently discovered Gtr2 GAP, Lst4-Lst7, is promoted and when combined with the effects of SEACIT inhibition, results in the active Gtr1(GTP)-Gtr2(GDP) configuration [117]. This stabilizes the association between EGO and the TORC1 subunits Kog1 and Tco89, leading to activation of the TORC1 complex [49, 61, 114, 118].

Mammals

The lysosome is the critical amino acid sensing organelle in mammals, and functionally, it is quite similar to the yeast vacuole. The Ragulator complex resides on the lysosomal surface and is analogous to the EGO complex found in yeast. Ragulator consists of a scaffolding subunit p18 (LAMTOR1, analogous to Ego1), a heterodimer of p14 and MP1 (LAMTOR2 and LAMTOR3, analogous to Ego3), and a heterodimer of C7orf59 and HBXIP (LAMTOR4 and LAMTOR5, suggested analogy to EGO2) [119-123]. Additionally, Ragulator is associated with a heterologous pair of Rag GTPases, RagA/B and RagC/D. Regulation of these GTPases occurs in response to nucleotide loading, very similar to how Gtr1 and Gtr2 function in yeast. Specifically, when amino acids levels are sufficient, Ragulator’s intrinsic RagA/B GEF activity is stimulated by the v-ATPase, the RagA/B GAP activity of GATOR1 is diminished, and the RagC/D GAP activity of FLCN-FNIP1/2 is activated [123-126]. These events coordinate the active nucleotide configuration of the Rag GTPases, with GTP-bound RagA/B and GDP-bound RagC/D [127]. In their active conformation, the Rag GTPases function to bridge mTORC1 and the lysosome [128]. At the lysosomal surface, mTORC1 is activated via interactions with the Rheb1 GTPase [129]. A recent study from Fawal et al. suggests that in addition to amino acid dependent spatial regulation of mTORC1, there may be a
mechanism in place which also links amino acid availability and the cellular distribution of Rheb1 [130]. The group identified microspherule protein 1 (MCRS1) as a critical mediator of Rheb lysosomal localization and nucleotide loading status in an amino acid-dependent fashion. Until recently, it was unclear how cells relayed amino acid levels in the lysosomal lumen to the Ragulator complex and mTORC1. A number of groups now report that the transmembrane solute carrier SLC38A9 is able to monitor amino acid accumulation in the lysosomal lumen and interact with the Ragulator complex in an amino acid-dependent fashion [131-133]. In total, activation of mTORC1 requires significant spatial and temporal coordination, as the Rags are responsible for promoting mTORC1’s localization to the lysosome, MCRS1 is responsible for bringing active Rheb to the lysosome, and Rheb is responsible for activation of mTORC1 [128].

The oncoprotein Rab1A was also recently identified as an amino acid responsive activator of mTORC1, but interestingly, it does so independently of the Rag GTPases [134]. Rab1A is overexpressed in colorectal cancer and this correlates with tumor invasiveness and an overall poor prognosis. High levels of Rab1A means cells are far more sensitive to amino acid starvation. In fact, they require high levels to continue growing and are said to be nitrogen “addicted”. Altogether, this suggests that deregulation of amino acid signaling through mTORC1 can contribute to cellular dysfunction and organismal disease.

TORC1’s Nuclear Functions

Given the array of environmental stimuli that influence TORC1 activity, and the role TORC1 plays in regulating the cell cycle, gene expression and anabolism, the complex is uniquely qualified to serve as a link between nuclear processes and nutrient availability. Yet to date, most of what is known about TORC1 is in reference to its cytoplasmic functions. This is due in large part to a number of publications in both yeast and mammalian cell culture models that suggest the majority of TORC1 resides in the cytoplasm, and more specifically, at the vacuole/lysosomal compartments [119, 124, 128, 135]. And while this view represents the historical understanding of TORC1, it fails to account for an emerging body of literature which has identified a role for nuclear-localized Tor kinase, and even components of TORC1, in transcriptional regulation [136-139]. There is still a considerable amount of research to be done in order to fully understand the nuclear functions of Tor kinases. However, the fact that TORC1 can be found in the nucleus, and even at specific gene promoters, means that the complex may directly bridge environmental status to cell cycle regulation, gene transcription, and/or the epigenome.

Effects on ribosomal DNA transcription

Traditionally, there have been two levels at which TORC1 can affect transcription, particularly as it relates to ribosome biogenesis. The first involves regulation of RNA polymerase I (RNAPI) promoter binding through phosphorylation of
Rrn3 (TIF-IA in mammals); an integral transcription factor which localizes to the rDNA to recruit RNAPI. At the rDNA, RNAPI is responsible for production of the 35S pre-ribosomal RNA (rRNA), which is ultimately co-transcriptionally processed into the 25S, 18S, and 5.8S rRNAs. These rRNAs are critical components of the ribosome machinery. Inhibition of TORC1 results in a rapid redistribution of RNAPI from the nucleus to the nucleoplasm, as well as enhanced Rpd3 binding to the rDNA [140, 141]. Subsequent Rpd3-dependent histone H4 lysine 5 and 12 deacetylation promotes condensin complex association, which compacts and stabilizes chromatin leading to decreased nucleolar volume [140, 142]. There is controversy in the field as to whether the RNAPI redistribution is a consequence of Rpd3-dependent transcriptional repression (via deacetylation), or is independent of Rpd3 [140, 143]. TORC1 has also been identified as a regulator of RNAPII-dependent RP gene expression, and RNAPIII-dependent 5S rRNA and tRNA production. It does so via Sch9-dependent phosphorylation of RP transcription factors such as Rtg1/3, Gln3, Tod6 and Dot6, or the RNAPIII negative regulator Maf1 [75, 86, 144-149]. These phosphorylation events mediate both the activity and localization of these factors as was mentioned in the previous sections.

TORC1, sirtuins, and the epigenetic modification of histones

Besides the direct mediation of polymerase function and transcription factor localization, there seems to be a poorly characterized third layer of TORC1-dependent effects on gene expression that involves regulation of chromatin structure through histone post-translational modifications [12, 66, 150-152]. Work from our lab shows that direct inhibition of yeast TORC1, either through subunit deletion or rapamycin treatment, results in globally diminished histone H3 lysine K56 acetylation (H3K56ac); a mark tied to DNA repair, maintenance of rDNA copy number, and overall genomic stability [66, 153, 154]. We also demonstrate that TORC1-regulated H3K56ac influences RNAPI binding to the 35S rDNA, as well as binding of the key Pol I transcriptional regulators Hmo1 and the SSU processome [66]. Although the exact mechanism linking TORC1 to this acetyl mark is currently unknown, our previous data suggests that regulation of the sirtuin histone deacetylases may be involved. Specifically, deletion of HST3 or HST4 is sufficient to restore H3K56ac in a TORC1 mutant [66].

The sirtuins are a conserved, NAD⁺-dependent family of histone deacetylases that in yeast includes Hst1, Hst2, Hst3, Hst4 and Sir2 (summarized in Table 1-1). They are sometimes referred to as class III histone deacetylases. Interestingly, despite their varied functions, all seven human sirtuins (SIRT1-7) most closely resemble yeast Sir2 according to standard BLAST alignment [155]. The relationship between sirtuins and TORC1 is particularly interesting as both have been heavily discussed as regulators of aging [70, 81, 156]. As mentioned previously, inhibition of TORC1 with rapamycin or CR extends lifespan and, fascinatingly, activation of sirtuin function with resveratrol mimics these effects [70, 157-159]. As a whole, the sirtuins’ best characterized role in the cell is transcriptional silencing, particularly at the silent mating type loci, telomeres and rDNA. To date, there are only a few characterized substrates for the yeast sirtuins, including the non-histone protein Ifh1 (deacetylated by Hst1 and Sir2), and the histone residues
Table 1-1. Summary of sirtuin histone deacetylase localization and substrate specificity in yeast.

<table>
<thead>
<tr>
<th>HDAC</th>
<th>Subcellular Localization</th>
<th>Genomic Localization</th>
<th>Histone Substrates</th>
<th>Non-Histone Substrates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hst2</td>
<td>Primarily Cytoplasmic (shuttled out of nucleus [160, 164, 165])</td>
<td>Telomeric repeats, rDNA, Silent mating type loci, Stationary phase granules [165-167]</td>
<td>H4K16Ac [168]</td>
<td></td>
</tr>
<tr>
<td>Hst4</td>
<td>Primarily Nuclear (shuttles to mitochondria [160, 176])</td>
<td>Telomeric repeats, rDNA, Silent chromatin, Sites of DNA repair [153, 169-173]</td>
<td>H3K56Ac [154, 174, 175]</td>
<td></td>
</tr>
<tr>
<td>Sir2</td>
<td>Primarily Nuclear [160]</td>
<td>Telomeric repeats, rDNA, Silent mating type loci [13, 161, 172, 173]</td>
<td>H3K4Ac [162], H3K9Ac [177], H4K16Ac [177, 178]</td>
<td>Ifh1 [163]</td>
</tr>
</tbody>
</table>
H3K4ac (deacetylated by Hst1 and Sir2), H3K9ac (deacetylated by Sir2), H3K56ac (deacetylated by Hst3 and Hst4), and H4K16ac (deacetylated by Hst2 and Sir2) [154, 162, 163, 168, 170, 174, 175, 177, 178]. The sirtuins are primarily found in the nucleus, with two exceptions; Hst2 is actively shuttled from the nucleus to the cytoplasm in a Crm1-dependent fashion due to the presence of a nuclear export signal [164], while Hst4 is known to move from the cytoplasm to the mitochondria in response to biotin starvation [176]. A similar shuttling phenomena is also seen with the mammalian sirtuins, SIRT1 and SIRT2 (see Table 1-2).

Hst3 and Hst4 are unique in that they appear to be regulated in a cell-cycle dependent fashion. The protein levels of Hst3 fluctuate throughout the cell-cycle in response to Mec1- or Cdk1-dependent phosphorylation, which promotes SCF<sup>Cdc4<sub>Cdc4<sup>-dependent polyubiquitination and degradation via the proteasome [179, 180]. A high-throughput screen designed to identify phosphoproteins that bind the SCF<sup>Cdc4<ub ubiquitin ligase determined that Hst4 may be regulated in a similar fashion [181]. Importantly, the phosphatase that opposes these SCF<sup>Cdc4<ub binding phosphomarks is still unknown.

Of all the sirtuins, the best characterized is Sir2. Its role in cellular aging and CR-mediated lifespan extension has been investigated over the last decade, with many groups linking deletion of <i>SIR2</i> to rDNA instability and yeast senescence [13, 69, 182, 183]. Specifically, inhibition of yeast TORC1 promotes rDNA association of Sir2, possibly in concert with the RENT complex, ultimately resulting in a hypoacetylated and deactivated rDNA chromatin architecture [13]. Sir2-dependent rDNA deacetylation enhances stability, suppresses extra-ribosomal circle formation, and significantly extends yeast replicative lifespan [13].

There are also noted interactions between mTORC1 and sirtuins in mammals. For example, SIRT4 gene expression is tied directly into glutamine metabolism via mTORC1 [184]. When amino acids are limiting, mTORC1 promotes proteasomal destruction of CREB2, a transcriptional regulator of SIRT4, which ultimately results in a decrease in SIRT4 levels. In this way, mTORC1 can modulate activation of the glutamine dehydrogenase promoter, a critical regulatory step in the production of key TCA cycle metabolites. There are a number of cancers that display aberrant SIRT4 expression, suggesting that dysfunctional mTORC1 activity may promote transformation through altered cell metabolism at the level of chromatin regulation. A second mammalian sirtuin, SIRT1, has been identified as a negative regulator of mTORC1 via interactions with the upstream TSC complex [185]. Interestingly, SIRT1 overexpression can complement loss of Sir2 at the level of rDNA stabilization, and SIRT6 (like Hst3 and Hst4) deacetylates H3K56ac, suggesting there is evolutionary conservation of function of these enzymes [177, 186].

A number of fascinating genetic interactions between TORC1 and histone H3 suggest signaling through the TORC1 pathway, or TORC1-mediated epigenetic modifications, may directly influence other chromatin-based processes. Our laboratory screened individual mutants of the majority of residues on the H3 and H4 tails and found only one, H3K37, whose maintenance is indispensable in response to decreased TORC1
Table 1-2. Summary of sirtuin histone deacetylase localization and specificity in mammals.

<table>
<thead>
<tr>
<th>HDAC</th>
<th>Subcellular Localization</th>
<th>Histone Substrates</th>
<th>Non-Histone Substrates</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIRT1</td>
<td>Actively shuttles between nucleus and cytoplasm, primarily nuclear [187, 188]</td>
<td>H3K9Ac [177], H4K16Ac [177, 189, 190], H3K9me2 [191] (indirect)</td>
<td>LC3 [192, 193], Atg5/7/8 [194], p300 [195], MOF [196], Tip60 [197, 198], p53 [199-201], FOXO factors [202, 203], NFκB [204], c-Myc [205], HIF-1α [206-208], PGC-1α [209], LKB1 [210], Ku70 [211], PARP1 [212, 213]</td>
</tr>
<tr>
<td>SIRT4</td>
<td>Mitochondrial [187, 221, 229]</td>
<td></td>
<td>GDH [230]</td>
</tr>
<tr>
<td>SIRT5</td>
<td>Mitochondrial [187, 221]</td>
<td></td>
<td>CPS1 [231, 232]</td>
</tr>
<tr>
<td>SIRT6</td>
<td>Nuclear [187, 233]</td>
<td>H3K9Ac [234-236], H3K18Ac [237], H3K56Ac [236]</td>
<td>CtIP [238]</td>
</tr>
<tr>
<td>SIRT7</td>
<td>Nucleolar [187, 239]</td>
<td>H3K18Ac [240]</td>
<td></td>
</tr>
</tbody>
</table>
activity [152]. These dramatic phenotypes are independent of glucose-dependent Ras/PKA signaling, suggesting the linkage between TORC1 and H3K37 is specific. Interestingly, because TORC1 is also sensitive to glucose, this may indicate that H3K37 is more strongly coupled to the amino acid sensing arm of TORC1. Mutation of this lysine to an alanine (H3K37A) results in a dramatic redistribution of high mobility group proteins (HMGs), including Nhp10, from chromatin to the cytoplasm accompanied by accelerated chronological aging. This is particularly fascinating considering that Nhp10 is a member of the INO80 chromatin remodeler, and TORC1 has already been shown to affect transcription through altered recruitment of histone chaperones and chromatin modifying complexes [241, 242]. A number of other remodelers are also anchored to chromatin through their HMG-containing subunit, a family of structural proteins that will be discussed further below.

High-Mobility Group Proteins: “The Architectural Transcription Factors”

HMGs are highly charged, extremely abundant, and the second most common protein found on chromatin besides the histones. There are three families of HMGs in mammals: HMGA, HMGB and HMGN. All three compete with H1 for binding to the linker DNA, and weakening of this H1 association results in decreased chromatin compaction [243-245]. Because yeast do not have obvious HMGA and HMGN factors, the HMGB class will be our main focus. HMGB family members bind the minor groove of B-form DNA with relatively low sequence specificity to introduce sharp bends or kinks into the strand. They are particularly enriched at the nucleosomes flanking transcriptional start sites, but can also be found at four way DNA junctions and significantly under twisted DNA [246]. The effect HMGBs have on gene expression (stimulatory or inhibitory) is often context dependent. Some data suggest the HMGBs simply distort DNA to promote incorporation of the transcriptional machinery, while others argue that in addition to bending DNA, HMGBs may also bridge associations of basal transcription factors (ex. TBP) with the transcriptional machinery [247-250].

The best-characterized mammalian HMGB member is the prototypical HMGB1. It has been identified as the most mobile of all nuclear proteins, as it can traverse the entire nuclear compartment in just over a second [251]. Interestingly, during cellular apoptosis, HMGB1 movement in the nucleus ceases and it remains anchored to chromatin, though the mechanism regulating this process is unknown [251]. This effect is believed to promote severely under-acetylated heterochromatic DNA. *In vitro* nucleosome binding studies, conducted with an array of HMGB1 truncation mutants, identified a specific C-terminal acidic sequence of HMGB1 that is necessary to promote transcription [252]. Crosslinking experiments show that the acidic region functions to enable HMGB1 to associate with the nucleosome via the histone tails, and specifically H3. Kawase et al. followed up on this work, utilizing mass spectrometry to perform a characterization of the association between HMGB1 and the nucleosome [253]. They reported that the acidic C-terminal tail of HMGB1 makes direct contact with H3K36 and H3K37 on H3, suggesting these sites play a vital role in securing HMGB1 to chromatin. HMGB1 is released from chromatin during necrosis to promote the innate immune
response by binding the Toll-like and RAGE receptors on immune cells [251, 254]. Association of HMGB1 with its RAGE receptor in tumor cell mitochondria is essential for optimal mitochondrial function, enhanced ATP production, and the dysfunctional bioenergetics observed in tumor microenvironments [255]. The nuclear to cytoplasmic translocation, and subsequent extracellular secretion, of HMGB proteins in senescent cells also promotes the senescence-associated secretory phenotype (SASP), which increases cancer risk in aging tissues [256]. Considering all of the evidence described above, deregulation of HMGB chromatin binding in mammals, particularly as cells age, has the potential to be transformative.

Yeast HMGBs fall into two general categories based on the number and structure of their HMG domains: a single sequence-specific HMG box, or two relatively sequence-independent HMG boxes. There are seven known HMGBs in yeast, Hmo1, Nhp6a/b, Nhp10, 1xr1 [257-259], Rox1 [258, 260-262] and Abf2 [263-266]. We will elaborate on the function of the HMGs that are particularly relevant to this work; Hmo1, Nhp6a/b and Nhp10.

Hmo1 is probably the best-characterized member of the yeast HMGB family. Hmo1 is exclusively nuclear and organized into three domains, including a classical HMG box required for DNA binding and bending (“HMG Box B”), a non-traditional HMG box whose function is controversial (“HMG Box A”), and a lysine-rich C-terminal nucleolar targeting sequence that also contributes to DNA binding and bending [267, 268]. The HMG boxes can interact with one and other, and HMG box A is also able to associate with Hmo1’s C-terminal tail. Hmo1 chromatin binding promotes compaction, the introduction of DNA loops or bends, and SWI/SNF- and ISWIa-dependent chromatin remodeling [267, 269, 270]. Hmo1 is involved heavily in ribosome biogenesis, an anabolic process significantly regulated by TORC1 (discussed previously). It is highly enriched in the nucleolus (nucleolar/nucleoplasmic interface) on active rDNA, and also localizes to the promoter of the RP genes [66, 271-274]. An elegant complementation study by Albert et al. identified Hmo1 as an rDNA binding component of yeast Pol I [275]. The authors also demonstrated that Hmo1 has a robust genetic interaction with Rpa49, suggesting involvement in Pol I initiation.

Nhp6a and Nhp6b are functionally redundant HMG family members, although Nhp6a is expressed at much higher levels in the cell. They are homologous to mammalian HMGB1/2, and play a significant role in chromatin remodeling [276, 277]. Nhp6a contributes to the recruitment of the FACT histone chaperone complex, which promotes a chromatin state permissive for transcription, replication, and repair [278-281]. Nhp6a also enhances the nucleosome sliding ability of the SWI/SNF ATP-dependent chromatin-remodeling complex [269]. In vivo studies with Nhp6a find that even in the absence of its acidic domain, chromatin context is still a key determinant of genome-wide binding [279, 282]. Given these interactions with well-characterized mediators of chromatin structure, aberrant Nhp6a/b localization or abundance is certain to impact gene expression patterns and overall cellular function. And finally, similar to the mammalian HMGB1 [251, 254], the nuclear to cytoplasmic translocation of Nhp6A is a hallmark of necrosis suggested to occur as a consequence of chronological aging [283].
Nhp10 is somewhat unique as it is the only HMGB known to associate with the INO80 ATP-dependent chromatin remodeling complex [284]. Nhp10 functions in INO80 to bridge the remodeler’s interaction with phosphoH2A.Z at double strand breaks, and also to protect DNA ends from exonucleatic cleavage at the break site [284-287]. Sekiguchi et al. find that in strains where INO80’s catalytic subunit has been mutated, loss of EGO function is synthetically lethal, implicating INO80 in TORC1-dependent chromatin regulation [288]. As described above, Nhp10 chromatin binding also appears to be linked with TORC1 activity via the H3K37 residue, though the exact nature of this relationship is currently unclear [152].

**Tor Dysfunction and Age-Related Pathologies**

Aging is a very complex process which remains poorly understood at the molecular, cellular, and organismal level. Studies over the past several decades have identified significant overlap between lifestyle, environmental factors, and epigenetics in determining the long-term health and viability of an organism. Fascinatingly, TORC1 may lie at the center of all three of these. It is clear that as an organism ages, a number of pathologies become more prevalent, including cardiovascular disease, cancer, diabetes and dementia. These diseases are all believed to be driven at some level by mTORC1 hyperfunction, which is itself a result of aging [289]. But it remains unclear as to why overactive mTORC1 has such a profound effect on cellular physiology and longevity.

The apparent association of TORC1, sirtuins and chromatin dynamics is intriguing as they have all been heavily cited as regulators of aging. Yet to our knowledge, there is very minimal mechanistic understanding to link all three. Inhibition of TORC1 with rapamycin or CR extends lifespan [68, 70-74, 290], activation of sirtuin function through treatment with resveratrol mimics these effects [67, 157-159, 291], and deletion of sirtuins dramatically reduces lifespan [170, 292]. This fact is incredibly important because we will present data showing that TORC1 inhibition promotes sirtuin function and histone deacetylation through a novel subcellular accumulation and stabilization mechanism. Such a relationship could also explain why there is controversy regarding which target (mTor vs. sirtuins) would be best to pursue in slowing or reversing cellular aging (as reviewed by Sinclair) [290].

The majority of tissues in the body consist of a large population of post-mitotic, fully-differentiated cells, and a smaller stem cell niche tasked with replenishing and maintaining the population over time. Classical aging phenotypes are most often attributed to cellular chronological aging, which is marked by an overall decline in cell health and function, culminating in physiological defects on the organismal scale. Recent evidence in skeletal muscle and the brain suggests that the longevity and viability of both the long-lived post-mitotic populations, as well as their stem cell niches, depends on sustained maintenance of chromatin as cells mature/age. Jurk et al. demonstrate that upon proliferative cessation, mature neurons enter a senescent-like state marked by heterochromatinization, elevated ROS production, persistent DNA damage, and other
traditional indicators of the senescence-associated secretory phenotype [293]. These effects become more prominent and deleterious with age but can be partially reversed by CR. And although the authors do not address the nature of this effect, it does suggest the possibility that nutrient responsive TORC1 function may contribute to the development of age-related senescence. We are particular fascinated with the chromatin effects observed in these cells, because it is now known that chromatin states in non-mitotic neurons are not nearly as static as they once seemed [294-297]. Gong et al. show that in aging mouse brains, there is a notable shift in the epigenetic landscape, including the acetylation and methylation of H3/H4, and many of these same modifications are responsive to CR or rapamycin treatment [298]. Liu et al. report that maintenance of quiescence in skeletal muscle stem cells correlates to a unique epigenetic signature which degrades with age [299]. Corruption of these signatures, specifically a genome-wide overrepresentation of H3K27me3, results in heterochromatin accumulation which the authors speculate contributes to an observed loss of stem cell function with age.

The above demonstrates how chromatin deregulation contributes to loss of function in vital cell populations, which ultimately results in organismal aging. It is the goal of this dissertation to characterize the mechanism by which TORC1 activity affects these processes, and to evaluate their potential contribution to organismal viability and longevity. In other words, to functionally understand the intersection between an organism’s environment, lifestyle, and epigenome as it relates to health and longevity. The project presented below is guided by the following Specific Aims:

1. Define the contribution of TORC1 signaling to the regulation of histone acetylation modifications and elucidate the mechanisms involved.

2. Determine the impact that TORC1-regulated histone acetylation has on cellular functions.

3. Define the role of the poorly-understood TORC1 subunit Tco89 in TORC1 signaling and epigenetic regulation.

Addressing these Specific Aims will provide significant insight into TORC1-dependent coordination of epigenetic mechanisms under normal biological conditions, while also identifying how TORC1 dysfunction and epigenetic corruption may contribute to disease mechanisms on an organismal scale.
CHAPTER 2. MATERIALS AND METHODOLOGY

Yeast Strains, Plasmids, and Culture Conditions

All of the yeast strains and plasmids used in this work are described in Tables A-1 and A-2 (in Appendix A), respectively. Strains constructed in our lab, including gene deletions and epitope tags, were made using PCR-generated targeting cassettes as previously described [300]. Unless otherwise stated, cells were grown in YPD (1% yeast extract, 2% peptone, and 2% dextrose) at 30° C with shaking. For experiments conducted in synthetic complete media, dropout mix was incorporated and supplemented with the appropriate amino acids to compensate for the auxotrophy of the strains. All media components were purchased from US Biologicals or Research Products International (RPI). Phos-tag was purchased from Wako Chem. Rapamycin, nicotinamide, sodium butyrate, trichostatin A, L-methionine sulfoximine (MSX), 2-(N-morpholino) ethanesulfonic acid (MES), and caffeine were purchased from either Fisher Scientific or Sigma-Aldrich. Galactose was purchased from MP Biomedical. The concentrations of these reagents are noted in the text.

Cloning primers for Tco89 fragmentation and Tco89/Sit4 complementation studies were designed as discussed in the text and as previously described [300]. The open reading frames of TCO89 and SIT4 were cloned as C-terminal mono-FLAG fusions into the BamHI/XbaI (Tco89FL and fragments) or BamHI/EcoRI (Sit4FL) restriction sites of the pRS416ADH plasmid, which contains an ADH1 promoter and CYC1 terminator [301]. PSI/PRED prediction software was used to avoid disruption of any potential secondary amino acid structure (discussed in Chapter 5) [302]. See Table A-2 for more information.

Antibodies and Stains

Antibodies used in this work were obtained from the following; α-RPS6 (Abcam), α-phosphoS6 (Cell Signaling), α-FLAG (Stratagene), goat α-rabbit HRP conjugated secondary (Jackson), α-Myc 4A6 (Millipore), α-HA and α-Myc A14 (Santa Cruz), G6PDH (Sigma), α-FLAG (Thermo), goat α-rabbit FITC-conjugated secondary (Rockland). Histone antibodies were all obtained from Active Motif. IgA- and IgG-conjugated beads for immunoprecipitation were from Santa Cruz. For live cell work, 5(6)-Carboxyfluorescein diacetate (CFDA) vacuolar stain was obtained from Invitrogen, dihydroethidium (DHE) from Fisher, and Hoechst nuclear stain from Life Technologies. For fixed cells, the Vectashield mounting media containing DAPI was purchased from Vector Labs. The apoptosis and necrosis staining experiments were conducted using an AnnexinV-FITC apoptosis kit from Clontech, and YO-PRO-1, propidium iodide (PI) and SYTOX from Life Technologies.
Western Blotting and Statistical Analysis

Cells were grown to log phase (OD\textsubscript{600} $\approx$0.8) in the indicated media as described above prior to treatment with drug (rapamycin or MSX) or galactose (2% final concentration), unless noted. Typically, cultures were set up to double 3 to 4 times before reaching this OD, ensuring that the majority of cells were replicatively young and metabolically active. Cells were then transferred to 50 mL falcon tubes using sterile technique, pelleted in a tabletop centrifuge, and frozen at -80°C. Pellets were resuspended in pre-chilled cracking buffer (10 mM Tris pH 8.0, 150 mM NaCl, 0.1% Nonidet P-40, 10% glycerol, 1 mM DTT) with additional phosphatase, histone deacetylase, and protease inhibitors. Glass beads were added to each tube, and the cells were lysed using a cold-room bead beater (3x 30 sec pulse with 3 min on ice in-between). Supernate was clarified at 4°C and stored at -80°C. Extract concentrations were determined using a traditional Bradford assay, and 35 μg samples were resolved by SDS-PAGE and transferred to PVDF membrane. In the case of samples subjected to SDS-PAGE with Phos-tag additive (50 μM), the included manufacturer’s instructions were followed. Membranes were probed overnight at 4°C with primary Ab. The blots were washed in TBST (10% TBS, 0.1% tween) for at least an hour with buffer replacement every 15 minutes. The blots were then incubated in secondary Ab for between 2 and 4 hours before developing using autoradiography. Films were scanned and analyzed by ImageJ where denoted. For determining significance, we used a two-tailed, unequal variance, pairwise Student’s t-test. *p<0.05, **p<0.01, ***p<0.001.

Spotting Assays

Cells were grown overnight at 30°C with shaking to saturation. OD\textsubscript{600} readings were taken and equivalent numbers of cells were aliquoted into column A of a sterile 96-well culture plate (see formulas below). The volumes in column A were made up to 200 μL with sterile water.

$$200 = \mu L \text{ cells} \times \frac{OD_{600} \text{ of stationary culture}}{\mu L H_2O}$$

Five-fold serial dilutions were then performed in which 40 μL of column A were transferred into 160 μL of water in column B and so forth. Cells were spotted to plate media and incubated as noted. Images were taken daily for 5-7 days using a UVP Digital Imaging System.

RT-qPCR

cDNA was synthesized from DNase I treated cellular RNA using random hexamer primers and the ImProm II reverse transcriptase system from Promega. Gene specific qPCR was conducted and normalized to the SPT15 housekeeping gene as previously described [303]. Primers are available upon request.
Indirect Immunofluorescence Confocal Microscopy

For studies regarding sirtuin localization, the following technique was utilized. First, cells were grown to log phase and treated as indicated. The cells were then fixed with 37% formaldehyde, pelleted at 800xg for 4 minutes, and washed twice with 4 mL of 0.1 M potassium phosphate buffer (K2HPO4, pH=6.5) and once with 4 mL P solution (1.2 M sorbitol, 0.1 M K2HPO4, pH=6.5). Pellets were then gently resuspended in 1 mL P solution and incubated at room temperature with 15 μL zymolase (15 mg/mL in P solution) and 5 μL β-mercaptoethanol for 25 minutes. Cell wall digestion (spheroplasting) was confirmed using a phase contrast microscope. After spheroplasting, cells were gently pelleted and resuspended in 150 μL of P solution. The resulting suspension was aliquoted to a poly-lysine coated slide and cells were allowed to settle for 20 minutes prior to blocking (8% bovine serum albumin/PBS/0.5% Tween 20). Slides were then placed in a humidified chamber and incubated in primary antibody overnight at 4°C. Following primary incubation, slides were washed four times with blocking solution, prior to the addition of fluorophore-conjugated secondary antibody (60 minutes at room temperature). From here on slides were protected from light. After the secondary incubation, slides were washed four times with blocking solution and twice with PBS. Finally, a drop of DAPI-containing Vectashield mounting media was placed on the slides and coverslips were positioned and sealed. Samples were imaged with the 63x oil Olympus objective on a Zeiss LSM 700 confocal microscope.

Direct Immunofluorescence Confocal Microscopy

For studies measuring HMG localization, cells were grown to log phase in duplicate 10 mL cultures and treated as indicated. Treatments often occurred over 60 minutes, so immediately following addition of drug, the process to image the untreated cells began. Untreated cells were spun down, washed with sterile water, transferred to a microfuge tube and pelleted. The cells were then resuspended in 100 μL sterile water with 2 μL Hoechst and incubated with agitation away from light for 15 minutes. Finally, the untreated cells were spun down, resuspended in 10 μL sterile water with 0.5 μL Hoechst and cover slipped as quickly as possible to avoid effects the altered nutrient state may have on the results. Slides were imaged with the 63x oil Olympus objective on a Zeiss LSM 700 confocal microscope. Following the one hour incubation of the treated cells, the above steps were repeated.

Image Analysis in Zen 2 Blue

In order to quantitate the subcellular localization of the tagged proteins, images taken on the Zeiss LSM 700 were analyzed in the Zen Lite Version 2.0.0 software program (blue edition) as previously described [304]. Briefly, using the Spline Contour tool, a border was drawn around the outer edge of each cell. Then, a second border was drawn around the nucleus. Upon closure of each border, information was provided, including the area within the border, and the mean intensity of each channel inside that
space. The mean intensity value for the green channel within the nucleus was multiplied by the area within the nuclear border to obtain our total nuclear fluorescence intensity (TNFI).

\[
TNFI = \text{nuclear mean intensity value} \times \text{nuclear area} \ (nm^2)
\]

This calculation was repeated for the values from the outer cell border, providing us a value we refer to as the total cellular fluorescence intensity (TCFI).

\[
TCFI = \text{cellular mean intensity value} \times \text{cellular area} \ (nm^2)
\]

From there, we simply divided the total nuclear intensity by the total cellular intensity and multiplied by 100 to get the percentage of our protein of interest that resides in the nucleus.

\[
\% \text{nuclear} = \frac{TNFI}{TCFI} \times 100
\]

Analysis fields were chosen at random, with approximately 20-40 cells quantified per condition, per independent biological replicate (4-6 replicates). Cells with a cellular mean intensity value under 50 units were excluded from calculations as we believe this is the threshold of adequate immunostaining.

**Sirtuin Turnover/Half-Life Analysis**

Cells were grown to log phase in 200 mL YPD flasks. At T₀, 50 mL aliquots were sterilely sampled from each sample, pelleted, and frozen. Cycloheximide (CHX) was then added to each flask at a concentration of 100 μg/mL. 50 mL aliquots were retained as described above at the time points indicated. Whole cell extracts (WCEs) were prepped and analyzed by α-Myc immunoblot. Films were scanned, quantified with ImageJ, and sirtuin signals were normalized to total protein via G6PDH.

**Apoptosis, Necrosis, DHE and CFDA Assays**

For analysis of apoptosis and necrosis, log phase cells were pelleted, washed twice with sterile PBS, and incubated for 20-30 minutes in the respective dyes: PI (50 μg/mL) and YO-PRO-1 (10 μM). Cells were then transferred to flow cytometry tubes, processed on a BD LSRII flow cytometer, and analyzed using FLOWJO V10. DHE (30 μM) and CFDA (100 μM) staining experiments were identical to the above except for the use of the different stains, and the retention of cells for additional confocal analysis.
Scoring for Tco89 Fragment Phenotypes

WT and tco89Δ cells were transformed with control vector or Tco89 N-terminal truncation fragments as indicated, grown to saturation, and spotted as detailed previously (see “Spotting Assays” section of this chapter). Growth on the spotting plates was scored as described by Rizzardi et al. [305]. Briefly, mutants were scored on a scale of -3 to 3, with a score of 1 representing an approximate 5-fold difference in growth and a value of 3 being a 125-fold difference. Strains exhibiting growth defects compared to wild-type cells received a negative value, while those with enhanced growth were given a positive value. A value of 0 indicates growth essentially equivalent to the control. Scores from at least five independent transformations were averaged, and a heat map was constructed in Microsoft Excel.
TORC1 Mediates Site-Specific Histone H3 and H4 Acetylation in Response to Environmental Stress, Particularly Glutamine Starvation

Our previous work identified a connection between TORC1 and the control of global H3K56ac [66]. We wanted to determine whether this effect was unique to H3K56ac, or if TORC1 also regulated other acetylation states on the histone H3/H4 tails. To do so, wild-type and tco89Δ cells were grown to log phase and wild-type cells were either mock or rapamycin treated (300 nM) for 60 minutes. The concentration and length of rapamycin treatments selected were confirmed to diminish TORC1 activity by phosphoS6 blot (Figure B-1 in Appendix B). WCEs prepared from these samples were screened for alterations to distinct histone acetylation states by immunoblotting (IB) with the indicated antibodies (Figure 3-1A). Films were scanned and analyzed by ImageJ, and relative histone acetylation was calculated by normalizing to total H3 with the mock treated samples set to 1 (graphed in Figure 3-1B). As shown in Figure 3-1A, TORC1 inhibition resulted in a dramatic site-specific reduction of acetylation at H3K18 (H3K18ac), H3K23 (H3K23ac), and H4K12 (H4K12ac), while other acetylation states were unaffected. These changes cannot be attributed solely to downregulation of transcription-coupled marks as we find that H3K4me3, a histone modification that demarcates actively transcribed genes, was unaffected. Loss of these histone modifications is unlikely to be explained by indirect consequences of TORC1 inhibition, since the acetylation reduction was observed as early as 20 minutes post-rapamycin treatment (Figure 3-1C). Furthermore, we demonstrated that exogenous Tco89 expression in the tco89Δ rescued acetylation, thus confirming that reduction of histone acetylation was due solely to the loss of this TORC1 subunit (Figure 3-1D).

Nitrogen metabolism, described in Chapter 1, is an established activator of TORC1 via the vacuolar-localized EGO and v-ATPase complexes. Prior evidence suggested carbon metabolism may regulate many of the histone acetylation states identified in Figure 3-1A [306]. Therefore, we next compared the impact of these nutrient signals on our sites of interest to determine whether the mechanisms which link carbon and nitrogen to the epigenome are overlapping, via TORC1, or are distinct. We first utilized the glutamine synthetase inhibitor MSX to block glutamine biosynthesis and impair nitrogen metabolism (Figure 3-2A). Treatment with 2 mM MSX mimicked the decrease in H3K18ac that occurs in response to direct TORC1 inhibition (Figure 3-2B, upper panel and graph). We confirmed MSX treatment reduced TORC1 activity by α-phosphoS6 IB (Figure 3-2B, lower panel). However, changing the quality of the carbon source from glucose to non-fermentable carbon (glycerol) failed to affect acetylation in

---

Figure 3-1. TORC1 signaling coordinates site-specific lysine acetylation on a subset of histone H3 and H4 N-terminal residues.

A. Wild-type (WT) and tco89Δ cells were grown to log phase and subjected to mock or 300 nM rapamycin treatment for 60 minutes. Cells were harvested and whole-cell extracts (WCEs) were analyzed by immunoblot (IB) with the indicated antibodies. 

B. ImageJ quantification of the results from (A). Data are representative of four or more biological replicates. Means and standard deviations (SDs) are provided, and significance was determined by pairwise Student’s t-test. *-p<0.05; **-p<0.01; ***-p<0.001.

C. As in (A), except WT cells were treated with 200 nM rapamycin for 20 minutes.

D. WT and tco89Δ cells were transformed with control vector (CV) or Tco89-9xMyc expression vectors and WCEs were analyzed as in (A).
Figure 3-2. TORC1-dependent histone acetylation is responsive to nitrogen, but not carbon, limitation.

A. Schematic showing the step in the glutamine biosynthetic pathway inhibited by MSX [307, 308].

B. WT cells were cultured to log phase and then mock treated or treated with 2 mM MSX for 20 minutes. Cells were harvested and extracts were analyzed by immunoblot with the indicated antibodies. ImageJ quantification was conducted, and a graphical representation of the mean and SD obtained over 9 independent experiments is provided. Significance was determined by pairwise Student’s t-test. ***p<0.001.

C. WT and tco89Δ cells were grown to log phase in YP 2% glucose or YP 2% glycerol. Extracts were prepared as above and blotted with the indicated antibodies.
either the wild-type or the \texttt{tco89A} mutant (Figure 3-2C). Given that cells grow more slowly in non-fermentable carbon, these findings also ruled out the possibility that the acetylation differences in \texttt{tco89A} are attributable to the reduced growth rate of this mutant. All together, these findings suggest a mechanism in which TORC1 activation, in response to nitrogen metabolism, functions to regulate this subset of histone acetyl sites.

**TORC1 Signals through the Tap42-Sit4 PP6 Phosphatase Complex to Regulate Site-Specific Histone Acetylation Globally**

After defining the TORC1-regulated histone acetylation states on histones H3 and H4, we next wanted to identify which TORC1 downstream effector was responsible for mediating these changes. Initially, we examined whether the TORC1-activated Sch9 kinase contributed to the control of these histone modifications using a series of previously described Sch9 expression vectors [80]. These included vectors expressing wild-type Sch9 (Sch9\texttt{WT}), a mutant form of Sch9 in which the TORC1 phosphotarget sites have been changed to alanines to prevent activation (Sch9\texttt{5A}), and another mutant Sch9 with those same sites mutated to acidic residues to mimic constitutive TORC1-dependent Sch9 phosphorylation (Sch9\texttt{2D3E}). We first demonstrated that wild-type and mutant Sch9 were expressed at relatively similar levels, thus ruling out the possibility that these mutations altered protein stability (Figure B-2A). From there, a series of control experiments were conducted, beginning with confirmation that in an \texttt{sch9A} mutant, introduction of the Sch9\texttt{2D3E} plasmid enabled growth on non-preferred carbon sources and rapamycin (Figure B-2B). We also determined that the mutant plasmid promotes Maf1 phosphorylation (a direct substrate of Sch9) regardless of upstream TORC1 activity (Figure B-2C) [87]. These findings confirmed that the Sch9\texttt{2D3E} mutant did behave independently of TORC1 as expected. Introduction of the Sch9\texttt{2D3E} mutant into \texttt{tco89A} failed to rescue acetylation (Figure 3-3A). Furthermore, histone acetylation was not reduced in \texttt{sch9A} (Figure 3-3B). We conclude that the Sch9 kinase does not function downstream of TORC1 to regulate histone acetylation.

We next investigated whether the other well-characterized downstream TORC1 effector, Tap42, contributes to the regulation of histone acetylation. \textit{TAP42} is an essential gene, so we utilized \texttt{tap42A} cells possessing a plasmid-based temperature-sensitive (\texttt{ts}) Tap42 allele [309]. In Figure 3-4A, we confirmed these three \texttt{ts} strains are indeed acutely sensitive to heat stress. We chose to specifically analyze the \texttt{tap42A+tap42-106ts} mutant as it had the least dramatic temperature sensitivity, which we predicted would limit non-specific acetylation changes due to impaired viability. Wild-type and \texttt{tap42-106ts} mutant cells were grown to log phase at the permissive (25°C) temperature and then shifted to a non-permissive condition (30°C) for 1 hour. WCEs were prepared and histone acetylation was analyzed by IB. Strikingly, in cells whose TORC1 function was intact, simply inactivating Tap42 led to dramatically reduced H3K18ac (Figures 3-4B and C). Even at the permissive temperature, there was a specific reduction in TORC1-regulated H3K18ac but no effect on H3K9ac, which we know is not responsive to TORC1 (Figure 3-1A). These results demonstrate that TORC1 likely signals through a Tap42-associated phosphatase to regulate site-specific histone acetylation.
Figure 3-3. Regulation of histone acetylation downstream of TORC1 occurs independently of the Sch9 kinase.

A. Wild-type (WT) and tco89Δ cells were transformed with control vector (CV) or Sch92D3E-expression vector and grown to log phase in selective media before preparation of WCEs. Extracts were analyzed by immunoblot with indicated antibodies. B. WT, tco89Δ and sch9Δ cells were grown in YPD and WCEs were prepared. Analysis by immunoblot was conducted as indicated. Western blots and histone acetylation averages provided are representative of at least three independent experiments, normalized to H3, with corresponding WT samples set to 1.
Figure 3-4. TORC1-responsive histone acetylation is regulated in a Tap42-dependent fashion.

A. tap42Δ cells containing endogenously expressed wild-type Tap42, or various temperature sensitive mutants (tap42-11, -109, -106) [309], were grown to saturation, five-fold serially diluted, and spotted onto YPD. Plates were cultured at permissive (25°C), semi-permissive (30°C), and non-permissive (33°C) temperatures and images were taken on day 2. B. Cells from (A) were grown to log phase in liquid culture at 25°C before being shifted to 30°C for 1 hour. WCEs were prepared and analyzed by immunoblot. C. Quantification of results presented in (B). Data is representative of three biological replicates. Means and SDs are provided, and significance was determined by pairwise Student’s t-test. **-p<0.01; ***-p<0.001.
The Tap42-associated phosphatases are organized into modular complexes. Typically, they are structured such that Tap42 associates with a catalytic subunit, and one or more regulatory subunits. To identify which of the phosphatases is required for TORC1-regulated acetylation, we screened catalytic mutants of individual Tap42-associated phosphatase complexes (PPG1/\textit{ppg1Δ}, PP4/\textit{pph3Δ}, and PP6/\textit{sit4Δ}) for the loss of rapamycin-induced deacetylation. Since PP2A possesses redundant catalytic subunits (Pph21 and Pph22), we instead used a \textit{tpd3Δ} mutant, which eliminates the PP2A regulatory subunit and impairs PP2A function [310]. Notably, only deletion of \textit{SIT4}, the catalytic subunit of the PP6 phosphatase complex, prevented the rapamycin-induced loss of H3K18ac (\textbf{Figure 3-5A}). We saw an identical effect on H3K56ac in \textit{sit4Δ} cells before and after rapamycin, strengthening our hypothesis that TORC1 is mediating H3K18ac, H3K23ac, H3K56ac and H4K12ac through a conserved mechanism. Importantly, we show in \textbf{Figure 3-5B} that transformation of the \textit{sit4Δ} mutant with a Sit4 expression vector was sufficient to restore the rapamycin sensitivity of H3K18ac. Finally, the \textit{tco89Δ} acetylation defect was completely rescued in a \textit{sit4Δ tco89Δ} combinatorial mutant (\textbf{Figure 3-5C}), further demonstrating that TORC1 inhibition promotes loss of histone acetylation through the activation of the Sit4 phosphatase.

The PP6 complex is a heterotrimer consisting of Tap42, Sit4, and one of four Sit4-associated regulatory proteins (Saps). To probe whether a particular Sap was responsible for Sit4-dependent acetylation repression, we conducted a similar experiment as described in \textbf{Figure 3-5A}, except individual Sap deletions were screened. Loss of either the Sap4 (\textit{sap4Δ}) or Sap185 (\textit{sap185Δ}) subunits led to significant rescue of acetylation in rapamycin-treated samples (\textbf{Figure 3-6}). However neither mutant alone was sufficient to promote the rapamycin resistance observed in a \textit{sit4Δ} (\textbf{Figure 3-5A}). This suggests that while Sap4 and Sap185 are most likely linked to Sit4-dependent regulation of acetylation, there appears to be a degree of functional redundancy between the Saps in this regard.

Sit4’s best-known function in the cell is to regulate the NCR response by modulating the phosphorylation, and subsequent localization, of the transcription factors Gln3 and Gat1 [75, 113, 145]. When cells are starved for amino acids, Gln3 dissociates from the cytoplasmic anchor Ure2 and moves to the nucleus in a Sit4-dependent fashion. Nuclear Gln3 then activates transcription of genes required for the utilization of non-preferred nitrogen sources. Because TORC1 suppression promotes Gln3 nuclear localization through Sit4 activation, we probed whether induction of the NCR was required for the effect on histone acetylation.

While loss of Sit4 led to an increase in basal H3K18ac as expected, we found surprisingly that deletion of the NCR transcription factors, Gln3 or Gat1, did not result in a similar increase in acetylation (\textbf{Figure 3-7}). In support of the above, loss of the cytoplasmic anchor Ure2 did not phenocopy the \textit{tco89Δ} hypoacetylation response (\textbf{Figure 3-7}). Taken together, these data suggest that the PP6 protein phosphatase complex is responsible for connecting TORC1 to the regulation of histone acetylation and that Sit4’s contribution exists outside of the NCR response.
Figure 3-5. Sit4-catalyzed PP6 complex activity is required for TORC1-responsive histone acetylation.

A. Wild-type (WT), tpd3Δ, ppg1Δ, pph3Δ and sit4Δ cells were grown in YPD to log phase before treatment with 300 nM rapamycin for 60 minutes. WCEs were prepared and analyzed by immunoblot and ImageJ.

B. WT cells transformed with control vector (CV) and sit4Δ cells transformed with CV or full-length pSit4-FLAG, were grown to log phase in selective media and treated with rapamycin as in (A). Extracts were prepped and probed by immunoblot.

C. WT, tco89Δ, sit4Δ and tco89Δ sit4Δ were grown to log phase, extracts were prepared and blotted as described above. Data are representative of at least 3 independent replicates, with average histone acetylation values relative to H3 (mock set to 1) provided.
Figure 3-6. Regulatory subunits of the PP6 phosphatase complex display overlapping function in relation to TORC1-responsive histone acetylation. As in Figure 3-5A, except mutants are various Sit4-associated protein (SAP) deletions, including sap4Δ, sap155Δ, sap185Δ and sap190Δ. Blots are representative of at least 3 independent replicates and average histone acetylation values relative to H3 (mock set to 1) are provided.

Figure 3-7. Sit4-dependent, nitrogen-responsive chromatin modifications are separable from the canonical nitrogen catabolite response (NCR) pathway. Mutants of the Sit4-mediated NCR stress response, including ure2Δ, gln3Δ and gat1Δ, were grown to log phase alongside WT, tco89Δ and sit4Δ, and analyzed by immunoblot as indicated. Blots are representative of 3 independent replicates and average histone acetylation values relative to H3 (WT set to 1) are provided.
TORC1-Responsive Histone Acetylation Is Specifically Regulated by the Sirtuin Histone Deacetylases

In our previous analysis of TORC1-dependent regulation of H3K56ac, we reported that loss of either of the sirtuins, Hst3 or Hst4, in a tco89Δ background restored acetylation to wild-type levels. This prompted us to investigate whether these newly identified TORC1-dependent acetylation states were similarly regulated. Initially, we cultured wild-type and tco89Δ cells to log phase and mock treated or treated with nicotinamide, a naturally occurring pan-sirtuin inhibitor. Treatment with nicotinamide led to an increase in basal H3K18ac in wild-type cells, and also rescued the acetylation defect observed in tco89Δ (Figure 3-8A). Strikingly, tco89Δ cells treated with FK866, a compound which inhibits sirtuins by blocking NAD+ biosynthesis [311], displayed robust restoration of histone acetylation (Figure 3-8B, left panel). The effect of FK866 on acetylation in wild-type cells was negligible. A pathway exists in yeast by which active TORC1 represses transcription of PNC1, a gene which encodes a nicotinamidase that scavenges nicotinamide and shunts it into the NAD+ biosynthetic cycle [67]. This means that TORC1 suppression results in both a reduction in the level of sirtuin inhibitor (nicotinamide), as well as an increase in sirtuin co-factor availability (NAD+). We next asked whether increased PNC1 expression could explain our observed link between TORC1 and sirtuin-dependent histone deacetylation. Surprisingly, combining pnc1Δ with tco89Δ failed to rescue TORC1-dependent acetylation (Figure 3-8B, right panel).

To probe whether class I or II histone deacetylases were also contributing to the regulation of TORC1-dependent acetylation states, we initially utilized the pharmacological inhibitors sodium butyrate and trichostatin A. However, for unknown reasons, these compounds failed to provide effective HDAC inhibition (data not shown). To circumvent this issue, we combined tco89Δ with a gene deletion of the major class I (Rpd3) or class II (Hda1) histone deacetylases to ask whether loss of these HDACs would diminish TORC1-dependent deacetylation. While the rpd3Δ and hda1Δ single mutants displayed elevated acetylation across our residues of interest, combining these with a tco89Δ still led to a significant reduction in acetylation (Figure 3-9, compare 2nd and 4th lanes). These results further support the hypothesis that TORC1-dependent histone acetylation specifically involves suppression of the sirtuins. To gain a more complete understanding as to the contributions of each sirtuin, we created another set of combinatorial mutants that paired tco89Δ with individual sirtuin deletions. These strains were used to repeat the experiment in Figure 3-9. Strikingly, we found dramatic differences in the ability of these sirtuin deletions to rescue site-specific acetylation in tco89Δ (Figure 3-10A and B). For example, H3K18 is deacetylated primarily by Hst2, Hst3 and Hst4, while H3K23 is solely targeted by Hst4. In all, our findings support the idea that active TORC1 promotes acetylation of the H3/H4 N-termini via repression of the Sit4/Sap4 PP6 phosphatase and the sirtuin deacetylases, and that this novel mechanism does not involve changes in Pnc1 levels or NAD+ biosynthesis.
Figure 3-8. TORC1-PP6 catalyzed histone H3/H4 deacetylation is promoted by the NAD⁺-dependent sirtuin family of histone deacetylases. 
A. Wild-type (WT) and tco89Δ cells were grown to log-phase before mock or 25 mM nicotinamide (sirtuin inhibitor) treatment for 60 minutes. WCEs were prepared and immunoblotted as indicated. Blots are representative of 3 independent replicates and average histone acetylation values relative to H3 (WT mock set to 1) are provided. B. In left panel, as in (A) except cells were treated with 500 nM FK866. In right panel, WT, tco89Δ, pnc1Δ and tco89Δ pnc1Δ were grown and analyzed by immunoblot as indicated.

Figure 3-9. Class I and II histone deacetylases are not involved in the observed TORC1-PP6 hypoacetylation response. 
WT, rpd3Δ, tco89Δ, tco89Δ rpd3Δ, hda1Δ and tco89Δ hda1Δ were grown to log-phase. Extracts were prepped and analyzed by immunoblot. Blots are representative of 4 independent replicates.
Figure 3-10. TORC1-responsive histone acetylation is modulated by a subset of sirtuin histone deacetylases in a site-specific fashion.

A. Combinatorial tco89Δ sirtuin gene deletion mutants were grown and analyzed by immunoblot as indicated. B. ImageJ quantification of data shown in (A). Data are representative of at least four biological replicates. Means and SDs are provided, and significance was determined by pairwise Student’s T-test. *-p<0.05; **-p<0.01; ***-p<0.001.
Sit4 Activation Downstream of TORC1 Inhibition Promotes Hst4 Stabilization

Mammalian mTORC1 activity was previously shown to regulate glutamine metabolism and TCA cycle replenishment by transcriptional suppression of SIRT4 [184]. We speculated that TORC1 inhibition in yeast might function similarly by promoting deacetylation through an increase in sirtuin expression. To address this, we epitope-tagged the sirtuin genomic loci with a 9xMyc epitope in both WT and tco89Δ cells. Cells were grown, WCEs prepared, and expression was analyzed by immunoblot. We observed dramatic increases in Hst4 and Sir2 protein expression in the tco89Δ mutants relative to wild-type cells (Figure 3-11A). Given that we previously identified Hst4 as the only sirtuin able to control all of the TORC1-dependent acetylation modifications (Figure 3-10), we selected it for further examination across a variety of TORC1 inhibitory conditions. Short-term rapamycin and MSX treatment had no effect on Hst4 levels in wild-type cells; however, both tco89Δ and 60-minute exposure to rapamycin led to elevated Hst4 expression compared to the mock-treated wild-type cells (Figure 3-11B). Considering that 20-minute TORC1 inhibition was sufficient to reduce histone acetylation (Figures 3-1C, 3-2B), we were surprised to find that Hst4 levels did not significantly increase until later in the treatment period.

To assess the contribution of Sit4 to these dynamic changes in Hst4 protein levels, we engineered sit4Δ and tco89Δ sit4Δ into the Hst4-9xMyc background and again examined Hst4 expression. Excitingly, we found that deletion of SIT4 in the wild-type Hst4-tagged strain significantly reduced Hst4 levels, and the combinatorial mutant, tco89Δ sit4Δ, brought the elevated Hst4 levels observed in the tco89Δ single mutant back to approximately wild-type levels (Figure 3-11C, upper panel). We saw a much more muted response when the experiment was repeated with a series of sap4Δ mutants, a result consistent with the idea that there is functional redundancy among the Saps (Figure 3-11C, lower panel). Given TORC1’s known role in regulating transcription, we used qPCR and confirmed that the increase in Hst4 protein levels was not due to elevated HST4 mRNA expression (Figure 3-12). Therefore, these data suggest that the Sit4-dependent effect on Hst4 expression is either translational or post-translational in nature.

Hst3 exhibits rapid proteasomal turnover, in a cell-cycle dependent fashion, in response to Cdk1 phosphorylation and subsequent SCF<sup>Cdc4</sup> ubiquitination [179, 180]. The phosphatase that opposes Cdk1-dependent Hst3 turnover is currently unknown. Hst4 was also identified as a potential SCF<sup>Cdc4</sup> substrate, but its proteolytic turnover has not been studied in nearly as much detail. We next asked whether the Sit4-dependent increase in Hst4 protein levels could be explained by a reduction in Hst4 turnover. To assess this possibility, we utilized our wild-type and tco89Δ strains expressing Hst4-9xMyc, and we examined the kinetics of Hst4 turnover in each. Cells were grown to log phase and then treated with cycloheximide (CHX), an inhibitor of protein synthesis. Excitingly, we found that relative to wild-type cells, the tco89Δ promoted a significant increase in Hst4 stability (Figure 3-13A). We demonstrate this stabilization is Sit4-dependent, as the tco89Δ sit4Δ Hst4-9xMyc strain displays a turnover rate very similar to that of the wild-type. We conducted the same experiment with WT and tco89Δ strains possessing an Hst3-9xMyc epitope for comparison, and surprisingly, found that in addition to the
Figure 3-11. Reduced TORC1 signaling activates PP6 to increase Hst4 protein levels.

A. No tag, and WT or tco89Δ cells expressing indicated epitope-tagged sirtuins, were grown to log phase and analyzed by IB with Myc or G6PDH antibodies. B. No tag, WT Hst4-9xMyc, and tco89Δ Hst4-9xMyc cells were grown to log phase before treatment with MSX or rapamycin as indicated. WCEs were blotted for Myc and G6PDH and analyzed by ImageJ. Quantification of Hst4 levels relative to G6PDH are provided with the WT mock set to 1. C. No tag, WT Hst4-9xMyc, sit4Δ Hst4-9xMyc, sap4Δ Hst4-9xMyc, tco89Δ Hst4-9xMyc, tco89Δ sit4Δ Hst4-9xMyc, and tco89Δ sap4Δ Hst4-9xMyc cells were grown to log phase and analyzed as in (B). Blots and expression values are representative of at least 3 independent biological replicates.
Figure 3-12. PP6-dependent changes in Hst4 protein levels are not due to increased HST4 mRNA expression. 
Hst3, Hst4 and Sir2 mRNA expression in wild-type, tco89Δ, hst4Δ, and tco89Δ hst4Δ cells. Means and SDs are presented and the data is representative of five independent experiments. Significance was determined by pairwise Student’s T-test. **-p<0.01; ***-p<0.001.
Figure 3-13. PP6 activation downstream of TORC1 inhibition initiates a reciprocal shift in Hst3/Hst4 stability.

A. No tag, WT Hst4-9xMyc, \textit{tco89Δ} Hst4-9xMyc and \textit{tco89Δ sit4Δ} Hst4-9xMyc cells were grown to log phase and treated with 50 μg/mL cyclohexamide (CHX). Samples were taken just before CHX addition and then at subsequent intervals. Two exposures of the α-Myc blot are provided for clarity, and data quantification is shown on the right. Values are the mean and SD of four independent biological replicates, and significance was determined by pairwise Student’s t-test. *-p<0.05.

B. As in (A) except Hst3 stability is measured. Time points differ as indicated.
increase in Hst4 stability in the tco89Δ mutant, there is also a reciprocal decrease in Hst3 stability (Figure 3-13B). It is currently unclear whether this decrease is in direct response to the enhanced level of Hst4, or it is because Hst3 is a biologically relevant substrate of Sit4.

We next asked whether the Sit4-dependent change in Hst4 stability could be traced to direct opposition of sirtuin phosphorylation. To probe this possibility, we immunoprecipitated Myc-tagged Hst3 or Hst4 from WT and tco89Δ extracts and resolved them on Phos-tag containing SDS-PAGE gels. Phos-tag is a reagent that binds phosphorylated residues and reduces their electrophoretic mobility, allowing for more distinct resolution of phosphorylated compared to non-phosphorylated forms of a given protein. We observed a marked reduction in the slower migrating forms (phosphorylated) of both Hst3 and Hst4 in wild-type extracts treated with lambda phosphatase; however, no discernible difference was detected in the phosphorylation pattern of either sirtuin when wild-type and tco89Δ extracts were compared (Figure 3-14A). As a control, we repeated the experiment shown in Figure 3-14A using the downstream TORC1 phosphotarget Sch9 (Figure 3-14B). We found a dramatic downward shift in Sch9 mobility in both the lambda phosphatase treated sample, as well as the rapamycin treated sample, confirming that the Phos-tag reagent behaves as expected. In all, these findings identify a novel mechanism in which TORC1 inhibition promotes Sit4 activation and site-specific histone deacetylation via stabilization of Hst4. These effects appear to occur independently of a direct role for TORC1 in Hst4 phosphorylation status.

**Hst4 Nuclear Accumulation Occurs Rapidly as a Consequence of TORC1 Inhibition and Sit4 Activation, and Precedes the Increase in Hst4 Stability**

It was previously reported that metazoan SIRT1 and SIRT2, as well as yeast Hst2 and Hst4, actively shuttle between subcellular compartments in response to starvation, cellular stress or cell-cycle progression (summarized in Tables 1-1 and 1-2) [168, 176, 188, 222, 312]. As outlined in Chapter 1, the best-known function of Sit4 activation downstream of TORC1 inhibition involves regulation of transcription factor localization to coordinate the NCR response. We therefore considered whether Sit4/PP6 activity might stabilize Hst4 by altering its subcellular distribution. Utilizing the wild-type and tco89Δ sirtuin 9xMyc-tagged strains described above, indirect immunofluorescence (Figures 3-15 and B-3) and quantitative analysis (Figure 3-16A) was performed as detailed in Chapter 2. Of the five sirtuins, Hst4 exhibited the most significant alteration in cellular localization, as diffuse staining throughout wild-type cells was considerably more nuclear focused in tco89Δ (Figures 3-15, 3-16A, B-3D).

To determine whether the increase in Hst4 protein levels occurred before or after the nuclear accumulation of Hst4, we repeated the experiment described in Figure 3-16A, this time including an additional wild-type sample treated with 200 nM rapamycin for 20 minutes. Importantly, we saw that the 20-minute rapamycin treatment, which previously had very little effect on protein levels (Figure 3-11B), was sufficient to promote maximal nuclear accumulation of Hst4 (Figures 3-16B and B-3D). This
Figure 3-14. Hst3 and Hst4 phosphorylation state is independent of TORC1 function.
A. Wild-type (WT) Hst3-9xMyc, tco89Δ Hst3-9xMyc, WT Hst4-9xMyc and tco89Δ Hst4-9xMyc were grown to log phase and extracts were prepared. Hst3 and Hst4 were immunoprecipitated from 1 mg of extract, and the sirtuin bound IgG-conjugated beads then were treated with lambda phosphatase for 1 hour at 30°C as indicated. IP samples were resolved on 10% SDS PAGE gels containing Phos-tag (50 μM) and evaluated by α-Myc IB. Input gels were run in parallel where 35 μg extract was resolved on 10% SDS PAGE gel without Phos-tag present. B. As in (A), except Sch9-6xHA strains were utilized.
Figure 3-15. TORC1 suppression drives Hst4 nuclear accumulation in a Sit4-dependent fashion.

Wild-type, tco89Δ, and tco89Δ sit4Δ strains containing either no tag or a 9XMyr epitope on Hst4 were grown to log-phase, fixed, permeabilized, and imaged using indirect immunofluorescence as described in Chapter 2. Images are representative of at least five biological replicates. DAPI staining denotes the nucleus and the α-Myc (FITC) tracks the localization of Hst4.
A. Nuclear ratios of the sirtuins were determined from a series of images, as described in Chapter 2, and graphed. Means and SDs presented are representative of five or more biological replicates. Each replicate contained 20-40 randomly selected cells.

B. Wild-type Hst4-9xMyc cells were grown to log phase and mock or rapamycin treated (300 nM rap, 20 min) before analysis as described in (A). tco89Δ Hst4-9xMyc and tco89Δ sit4Δ Hst4-9xMyc strains were included for comparison. Significance was determined by pairwise Student’s t-test. *-p<0.05; **-p<0.01.

Figure 3-16. Hst4 nuclear accumulation occurs rapidly as a consequence of TORC1 inhibition and precedes the increase in Hst4 protein stability.
correlated well with the timing of the acetylation response (Figure 3-1C). Finally, in a tco89Δ sit4Δ Hst4-9xMyc strain, which displays a wild-type level of Hst4 expression and turnover (Figures 3-11C and 3-13A), the cellular distribution of Hst4 was corrected (Figures 3-15 and 3-16B). Therefore, Sit4 activation is required to promote Hst4 nuclear localization and rapid histone deacetylation (within 20 minutes), and the subsequent stabilization of this nuclear HDAC (60 minutes post-TORC1 inhibition) likely sustains the hypoacetylation phenotype until TORC1 activity is restored.

TORC1-Dependent Histone Acetylation Does Not Impact RP Gene Transcription, But Does Contribute to a Subset of TORC1-Regulated Biological Functions

TORC1 had been previously identified as a regulator of acetylation at the rDNA and the RP genes, and our lab recently characterized a critical role for TORC1-mediated H3K56ac in RNA polymerase I-dependent rDNA transcription [12, 13, 66, 140, 142]. Given this, and TORC1’s well-established link to anabolism, we next asked whether these TORC1-regulated acetylation states contributed to the transcriptional regulation of ribosome biogenesis. In the initial characterization of Tco89, it was reported that tco89Δ mutants had no effect on ribosomal protein gene expression [43]. However, we chose to revisit these claims as the authors did not present the data or identify the genes they had assayed. Utilizing cDNA from Figure 3-12, we examined how decreased acetylation (WT to tco89Δ), and subsequent restoration (tco89Δ to tco89Δ hst4Δ), impacted expression of a subset of RP genes encoding both small and large ribosomal subunits. We found that in the tco89Δ mutant, where TORC1 function is decreased (Figure B-1) and we observe a global site-specific reduction in acetylation (Figure 3-1A), there is not a significant effect on RP mRNA levels (Figure 3-17). The hst4Δ had a similarly negligible effect, while tco89Δ hst4Δ resulted in a moderate yet significant reduction in RPL23B expression (Figure 3-17).

tco89Δ mutants have been reported to enter an irreversible, growth-arrested state following TORC1 inhibition [49]. A number of characterized physiological states and compounds can promote this permanent growth-arrest, including nutrient starvation, rapamycin, the DNA damaging agent hydroxyurea, and the metalloid arsenic trioxide [57, 313]. And while the ultimate cellular response is often similar, the mechanisms underlying these effects can be very diverse [314]. We next determined if restoration of TORC1-regulated acetylation could rescue the sensitivity of tco89Δ mutants to these TORC1 inhibitors. Excitingly, we found that pairing an hst3Δ or hst4Δ with tco89Δ reversed its sensitivity to low dose rapamycin (5 nM), as well as to hydroxyurea and arsenic trioxide (Figure 3-18). These spotting data were surprisingly distinct from what was observed with the tco89Δ sit4Δ across the same spectrum of conditions. Although tco89Δ sit4Δ was sufficient to restore wild-type growth on hydroxyurea and arsenic, it failed to enable growth on rapamycin (Figure 3-18).

A previous study suggested that Hst4 may be the functional ortholog of the metazoan mitochondrial SIRT3 [176]. This study demonstrated that Hst4 localization to the mitochondria fluctuates in response to vitamin availability (biotin), and that this effect
Figure 3-17. Global loss of TORC1-responsive acetylation marks does not correlate with a change in expression of a subset of ribosomal protein genes. WT, tco89Δ, hst4Δ and tco89Δ hst4Δ cells were grown to log phase, cDNA was synthesized from total RNA, and qPCR was performed with the primer sets indicated. Data are the average and SD of four independent experiments and significance was determined by pairwise Student’s t-test. **-p<0.01.
Figure 3-18. TORC1-PP6 regulated histone acetylation is functionally significant for a subset of TORC1-dependent processes.

WT, tco89Δ, hst3Δ, tco89Δ hst3Δ, hst4Δ, tco89Δ hst4Δ, sit4Δ and tco89Δ sit4Δ were cultured to saturation overnight. Cells were five-fold serially diluted and spotted onto the indicated plate media. Images were obtained after four days at 30°C.
correlates with changes in mitochondrial protein acetylation, cellular respiration, and reactive oxygen production. Given the similarities between the biotin signaling mechanism, and the one we described above, we asked whether the nitrogen responsive TORC1-PP6-sirtuin cascade may also impact mitochondrial function. To explore this concept, wild-type, tco89Δ, hst4Δ and tco89Δ hst4Δ cells were either mock treated or treated with a low concentration (5 nM) of rapamycin for 2 hours. Cells were then stained with DHE to detect reactive oxygen species (ROS). TORC1 inhibition, via rapamycin treatment or tco89Δ, had relatively little effect on ROS production relative to wild-type mock-treated cells (Figure 3-19). In agreement with the biotin study [176], deletion of HST4 did indeed trigger a decrease in basal ROS levels in both the wild-type and the tco89Δ backgrounds (Figure 3-19). Considering TORC1 inhibition did not have an effect on ROS production, it would seem that the link between Hst4 and ROS occurs independently of our newly-characterized PP6-dependent mechanism. Still, this is an interesting development and provides insight into another biologically relevant function for this sirtuin.

In all, our data illustrate the existence of a novel TORC1-PP6-sirtuin signaling cascade that coordinates the epigenetic modification of histones with changes in environmental nitrogen availability. Further, we demonstrate that the downstream activation of sirtuins, in response to TORC1 inhibition, plays a critical role in an array of cellular operations, including cell cycle re-initiation following stress and DNA repair.
Figure 3-19. Hst4 contributes to cellular ROS levels independently of TORC1.

WT, hst4Δ, tco89Δ and tco89Δ hst4Δ cells were cultured to log phase and mock or rap treated (5 nM) for 2 hours. Cells were then washed and stained with DHE for 20 minutes prior to analysis by flow cytometry. Data presented are the average and standard deviations of five independent experiments. Significance was determined by pairwise Student’s t-test. *-p<0.05; **-p<0.01.
CHAPTER 4. HMG DISPLACEMENT OCCURS INDEPENDENTLY OF TORC1-MEDIATED HISTONE ACETYLATION TO PROMOTE A NOVEL, STRESS-RESPONSIVE CELL DEATH

H3K37A Mutation Correlates with HMGB Nuclear Delocalization and Is Sufficient to Change Rapamycin from a Cytostatic to a Cytotoxic Agent

Our lab previously identified a significant and unique genetic link between TORC1 signaling and one particular histone tail residue, H3K37 [152]. Using a library of histone mutants in which each residue has been individually mutated to alanine [315], we screened for altered sensitivity to the TORC1 inhibitor rapamycin. H3K37A turned out to be the only mutant in the library that, when treated with low doses of rapamycin, exhibited a dramatic loss of viability ([152] and Figure 4-1A). This rapamycin sensitivity proved to be independent of histone post-translational modification however, as replacing the native lysine with an amino acid that mimics acetylation (glutamine), or simply restores its charge (arginine), rescued the rapamycin phenotype (Figure 4-1A, lower panel). The only known function for H3K37 in the cell is to anchor HMGBs to chromatin [252, 253, 316, 317]. In previous work from our laboratory, we hypothesized that the cell death caused by TORC1 inhibition in H3K37A cells was attributable to nuclear delocalization of HMGBs [152]. Given the findings presented in Chapter 3, we sought to expand on this previous work to probe whether TORC1-regulated histone acetylation may contribute to the binding of HMGBs to chromatin.

Initially, we screened for other HMGB proteins that may behave similarly to the previously characterized Nhp10 [152]. We found that Nhp6a is also displaced from the nucleus in H3K37A cells following transient low dose exposure to rapamycin (Figure 4-1B). Nhp6a delocalization does not occur in an H3K37R mutant (Figure 4-1B), which fits with the fact that H3K37R cells are not sensitive to TORC1 inhibition (Figure 4-1A). Together, this shows that there is a strong correlation between HMGB delocalization and the overall health of the cells under TORC1-limiting conditions. Critically, while HMGB release into the cytoplasm occurred 60 minutes post-rapamycin treatment (Figure 4-1B), a significant increase in cell death was not observed until between 60 and 90 minutes post-rapamycin (Figure 4-1C). These data support our hypothesis that HMGB nuclear delocalization may drive induction of apoptosis/necrosis under TORC1-limiting conditions, rather than simply occurring as a consequence of cell death. We next asked whether H3K37A mutants would be less sensitive to rapamycin if Hst4 (the sirtuin opposing TORC1-dependent histone acetylation) or Sap4 (one of the ancillary PP6 subunits critical for stabilizing Hst4 under TORC1-repressive conditions) were deleted. \textit{hst4A} had no effect on Nhp6a localization (Figure 4-2A), nor did \textit{hst4A} or \textit{sap4A} restore cellular viability following rapamycin treatment (Figure 4-2B). Additionally, there was no significant growth advantage for the H3K37A \textit{hst4A} or the H3K37A \textit{sap4A} during transient or long-term rapamycin exposure (Figure B-4A and B-4B respectively). And finally, H3K37A mutants plated on media containing both nicotinamide and rapamycin did not show improved growth compared to rapamycin alone (Figure B-4C).
Figure 4-1. The H3K37A mutation correlates with HMGB nuclear de-localization and converts rapamycin from a cytostatic to cytotoxic agent.

A. Strains from a previously described histone mutant library [315] were grown to saturation, five-fold serially diluted, and spotted onto YPD control plates or YPD + 20 nM rapamycin. A cartoon illustrating relevant H3 N-terminal tail residues is provided, and H3K37 is highlighted in pink. See text for more details.

B. H3WT and H3K37A cells expressing Nhp6a-EGFP were either mock or 20 nM rapamycin treated for one hour. Confocal microscopy images were obtained and analyzed as described in Chapter 2. Quantification of this data is provided, with means and SDs plotted. Significance was determined by pairwise Student’s t-test. **-p<0.01.

C. H3WT and H3K37A were cultured to log phase and then mock or 20 nM rapamycin treated for increasing lengths of time as denoted below. Cells were stained with YO-PRO-1 and PI and analyzed by flow cytometry. Averages and SDs are representative of three independent experiments. Data source: personal communication with Dr. Hongfeng Chen, May 2016.
Figure 4-2. Partial restoration of TORC1 responsive histone H3/H4 acetylation does not reverse Nhp6A nuclear delocalization or cell death. 

A. H3WT and H3K37A expressing Nhp6a-EGFP, and the matched hst4Δ mutants, were either mock or 20 nM rapamycin treated for one hour. Confocal microscopy images were taken and analyzed as described in Chapter 2. Averages and standard deviations are presented, and are representative of at least 3 independent biological replicates. Significance was determined by pairwise Student’s t-test. *-p<0.05. B. H3K37A, H3K37A hst4Δ and H3K37A sap4Δ were cultured to log phase and then mock or 20 nM rapamycin treated for one hour prior to staining with YO-PRO-1 and PI and FACS analysis. The data are the average and SD of three independent experiments. Matched H3WT samples were analyzed in parallel (including sap4Δ and hst4Δ strains), however there was not any detectible apoptosis or necrosis in those samples. Data source for Figure 4-2A: personal communication with Dr. Hongfeng Chen, May 2016.
Overall, while these data do support a functional role for H3K37 as a vital contact residue for HMGB-chromatin binding under conditions of TORC1 inhibition, they argue against the hypothesis that TORC1-dependent acetylation contributes to this association. An alternative possibility could be that the TORC1-dependent chromatin changes detailed in Chapter 3 may function in parallel with H3K37 to suppress cell death. It is important to emphasize that we have demonstrated there is some functional redundancy amongst the sirtuins and Saps in their effects on histone acetylation. Therefore, in the absence of Hst4 or Sap4, additional Saps or sirtuins may partially compensate and thus, mask their potential contributions to this process. We chose to use these strains as we were unable to create an H3K37A sit4Δ mutant, which presumably would have had a greater effect on acetylation, and possibly rapamycin sensitivity.

**Aberrant HMGB Expression and Localization Result in Vacuolar Acidification and Apoptotic and Necrotic Cell Death through a Novel Death Pathway**

We next investigated the cell death mechanism triggered by HMGB displacement in H3K37A mutants following TORC1 inhibition. Previously, we noticed that the H3K37A cells displayed abnormal vacuolar morphology even prior to TORC1 suppression [152]. It was unclear at the time whether these vacuoles were dysfunctional, or if this was simply a sign of a compensatory increase in autophagy. We speculated that these changes in vacuole morphology may be linked to the cell death phenotype observed in TORC1-suppressed H3K37A cells. To explore this concept, H3 wild-type (H3WT) and H3K37A mutants were stained with CFDA, a dye which is used to visualize changes in vacuolar pH. Confocal microscopy analysis identified significant vacuole acidification in H3K37A mutants following 60 minute rapamycin exposure, whereas no change in pH was detected in similarly treated H3WT cells (Figure 4-3A). Importantly, the timing of acidification correlates with the nuclear release of HMGBs, which again, occurs prior to significant cell death (Figure 4-1C). Vacuole acidity was quantified by flow cytometry and steadily increased for hours in the rapamycin-treated H3K37A mutant (Figure 4-3B). There was no discernible change in the rapamycin-treated H3WT cells over this same period. Together, these results would suggest that cytoplasmic HMGBs may be promoting cell death, in part, via vacuolar dysfunction.

To demonstrate this vacuolar acidification is directly attributable to HMGB delocalization, we next asked whether aberrant HMGB expression caused a similar constellation of vacuolar effects in an otherwise wild-type cell. To accomplish this, we transformed H3WT cells with galactose-inducible Nhp6a or Hmo1 expression vectors. Cells were cultured in raffinose, treated with 2% galactose for 20 minutes, and then stained with CFDA and quantified by flow cytometry analysis. Unfortunately because vacuolar pH is highly responsive to metabolic changes, even transient galactose induction in minimal raffinose media led to increased acidity in the control cells, thus confounding data analysis (data not shown). Still, because the galactose-inducible promoter is leaky, confirmed by immunostaining for HMGB expression in the absence of galactose (Figure B-5), we attempted the experiment in minimal raffinose media without galactose induction. Excitingly, we were able to recapitulate the decrease in vacuolar pH by simply
Figure 4-3. Aberrant HMGB localization results in vacuolar acidification. 
A. H3WT and H3K37A cells were grown to log phase in YPD and then mock or 20 nM rapamycin treated for 20 minutes. Cells were stained with CFDA and imaged via direct confocal microscopy as described in Chapter 2. Arrows denote cells with increased vacuolar acidity. B. As in (A), except rapamycin treatment was extended to 1-3 hours and analysis was conducted by flow cytometry. C. H3WT cells transformed with control vector or galactose-inducible NHP6A or HMO1 vectors were grown to log phase in YP-Raffinose. Cells were then stained with CFDA and analyzed by flow cytometry. D. Quantification of the average and SD of the peak CFDA fluorescence of the entire gated population shown in (C). E. Quantification of the average cell number and SD of the bracketed population in (C). Data are representative of five independent experiments. Significance was determined by pairwise Student’s T-test. **-p<0.01; ***-p<0.001. Data source for Figure 4-3A: personal communication with Dr. Hongfeng Chen, May 2016.
deregulating HMGB expression/subcellular distribution in an otherwise wild-type cell (Figure 4-3C, D and E). We identified a shift in total CFDA signal (Figure 4-3C, quantified in 4-3D), indicative of a decrease in the average vacuolar pH. Additionally, we observed a change in the overall population distribution toward a more acidic pH (denoted by bracketed population in Figure 4-3C, quantified in Figure 4-3E).

Our time course experiments suggested that vacuole acidification occurred prior to any significant loss of viability (Figure 4-3B). However, it remained unclear whether the cell death downstream of TORC1-dependent HMGB displacement was directly caused by the decrease in vacuolar pH. To address this point, we incorporated MES into our plate media to ask whether pH buffering could rescue the H3K37A rapamycin phenotype. We found that the H3K37A cells were significantly less sensitive to rapamycin when cellular pH was buffered (Figure 4-4). These results further support our hypothesis that TORC1 inhibition in H3K37A, and the resulting HMGB delocalization, is an initiator of cell death through aberrant vacuolar acidification.

H3K37A Mutants Display Increased TORC1 Activity, Which Correlates with Displacement of HMGBs and Can Be Reversed by HMGB Deletion

Our findings to this point illustrate a strong correlation between HMGB delocalization and vacuolar dysfunction. We previously hypothesized that one reason the H3K37A mutant is hypersensitive to rapamycin is that, while H3K37 serves as the main chromatin docking site for HMGBs, TORC1-dependent histone acetylation states may contribute to HMGB chromatin binding as well. However, the data presented in Figure 4-2 would suggest instead that TORC1 signaling and HMGB binding may function in parallel to synergistically regulate cell survival. In the process of performing the experiments with the H3K37A hst4Δ and H3K37A sap4Δ strains (Figure 4-2), we serendipitously discovered that H3K37A mutants have a dramatic increase in basal TORC1 activity as demonstrated by S6 phosphorylation (Figure 4-5A).

Recently an insightful review was published by Eltschinger and Loewith [318] describing a series of feedback loops centered around TORC1. Given that TORC1 complex activation is tightly linked to vacuolar processes, we speculated that the nuclear displacement of these HMGBs downstream of TORC1 might alter vacuole function to feedback and affect complex activity. Strikingly, wild-type cells transformed with galactose-inducible HMG plasmids exhibited significantly elevated TORC1 signaling relative to control vector expressing cells (Figure 4-5B). Additionally, we found that genomic deletion of the HMGBs previously identified as having TORC1-responsive cytoplasmic localization (Nhp6a and Nhp10) was sufficient to reduce TORC1 signaling in both H3WT and H3K37A backgrounds (Figure 4-5C). This effect is specific as deletion of HMO1, a gene encoding an HMG whose nuclear localization was unaffected by both H3K37A and TORC1 inhibition [152], had no effect on TORC1 function (Figure 4-5C). Altogether, these findings confirm that delocalization of HMGBs in both H3WT and H3K37A backgrounds, particularly the nuclear to cytoplasmic translocation of
Figure 4-4. Buffering intracellular pH is sufficient to partially reverse the rapamycin sensitivity of an H3K37A mutant. H3WT and H3K37A cells were grown to log phase, five-fold serially diluted, and spotted to indicated media conditions. Data source: personal communication with Dr. Hongfeng Chen, May 2016.
Figure 4-5. H3K37A mutants display increased TORC1 activity that depends on the presence of specific HMGB factors.

A. H3WT and H3K37A cells were grown to log phase and mock or rapamycin treated (20 nM) for 60 minutes. Extracts were prepared and analyzed by IB as indicated.

B. H3WT cells transformed with galactose-inducible, HA-tagged, HMGB expression vectors were grown to log phase in raffinose media prior to 2% galactose induction for 20 minutes. Samples were processed and analyzed as in (A).

C. H3WT and H3K37A strains were constructed in which the indicated individual HMGB genes were deleted. Strains were grown up to log phase in YPD and analyzed by IB as in (A).
Nhp6a and Nhp10, is sufficient to promote vacuolar dysfunction and an overall increase in TORC1 activity.

In all, the work presented in this chapter suggests that H3K37 does indeed serve as a docking site for high-mobility group proteins \textit{in vivo}, though whether TORC1-responsive acetylation states contribute to HMGB chromatin binding is questionable. Disruption of HMGB chromatin association results in apoptotic and necrotic cell death marked by aberrant vacuolar pH and elevated TORC1 function.
CHAPTER 5. INVESTIGATING THE ROLE OF TCO89 IN TORC1

Identification of the Domain Necessary for Tco89-Dependent TORC1 Functions

Very little is known about the function of the *S. cerevisiae* TORC1 subunit Tco89, and structurally, we know virtually nothing. As was mentioned in Chapter 1, homologs have been identified in *S. pombe* and *C. albicans*, though curiously, it is currently the only yeast TORC1 subunit without an obvious mammalian ortholog [52, 53]. There is evidence that Tco89 bridges TORC1 and the vacuole [49], coordinates vacuolar function via Vac8 [62], and also regulates site-specific histone acetylation [66]. Previous studies summarized on the Saccharomyces Genome Database demonstrate that *tco89*Δ cells have abnormal cellular physiology and budding patterns, as well as dramatically increased sensitivity to heat, caffeine, MMS, rapamycin and salt [52, 54-60]. Allowing *tco89*Δ cells to reach stationary phase where nutrients are limiting, or treating them with rapamycin, results in an irreversible cell-cycle arrest [49, 61]. These effects demonstrate that loss of this subunit enhances cellular sensitivity to TORC1 inhibition. Interestingly, these mutants are also described as having a decreased rate of carbon and nitrogen metabolism [319]. We believe a better understanding of Tco89’s role within the complex could provide insight into whether a similar subunit exists within mammals. If so, targeting such a factor pharmacologically could greatly enhance the clinical efficacy of mTORC1 inhibitors.

We first wanted to identify the key domains of the protein required for its function. We constructed a series of N-terminal Tco89 truncation mutants, each displaying a C-terminal FLAG epitope tag. Very little is currently known about the structure of Tco89, so we utilized the PSI-PRED prediction profiling software as a guide for where to draw our boundaries between clones (Figure 5-1A) [302]. It was our hope that with this information we could avoid truncating in the middle of a domain, which would likely confound our analysis. Our cloning strategy is shown in full in Figure 5-1A. We demonstrated that all of our truncations are stable and expressed at approximately equal levels in Figure 5-1B. While the particular blot presented in Figure 5-1B appears to have less of clone B present, we note that this is not a consistent result. There seemed to be a degree of fluctuation across the independent transformations which is not currently understood, but we never observed a pattern that would suggest one clone is more or less stable than the rest, nor did these fluctuations ever seem to correlate to a difference in screened phenotypes.

Wild-type and *tco89*Δ cells transformed with control vector, a vector expressing full-length Tco89, or various Tco89 truncations, were grown overnight to saturation. Equivalent numbers of cells were then serially diluted and spotted onto control selection plates, and selection plates containing rapamycin or caffeine (Figure 5-2A). The phenotype of each mutant grown on these various TORC1 inhibitors was qualitatively scored using a previously described method [152]. These values were averaged and are shown in heat map format in Figure 5-2B. Clearly, there is a dramatic difference in rapamycin sensitivity comparing fragment C to fragment D, which would indicate that
Construction of Tco89 mutant expression vectors.

**A.** Diagram of cloning strategy used to create a series of N-terminal truncations of the TORC1 subunit Tco89. Constructs contain a C-terminal FLAG epitope for visualization. PSI/PRED prediction software was used to locate probable secondary structure, and the software profile information is provided [302]. Predicted α helices are denoted in red and β strands in blue.

**B.** tco89Δ cells were transformed with control vector (CV), or vectors containing full-length Tco89 (FL) and the truncations (A-F). Transformants were grown to log phase under selection, and whole cell extracts were prepared and blotted for FLAG to confirm expression. Arrows denote the seven Tco89 truncation fragments. G6PDH is provided as a loading control.
Figure 5-2. Identification of the functional domain necessary for Tco89-dependent TORC1 functions.

A. WT cells transformed with control vector, and tco89Δ strains expressing the series of Tco89 truncation vectors, were grown to stationary phase, five-fold serially diluted and spotted to TORC1 inhibitory conditions as indicated. Images are representative of growth following four days incubation. Growth on various conditions was scored on a -3 to 3 scale as described previously [305], and in Chapter 2.

B. Quantification of growth phenotype scores from (A). Data is presented as a heat map, with red indicating decreased growth compared to wild-type, white indicating no change, and green representing an increase in viability. Scores are the average obtained from at least five independent transformations.

C. Strains of interest from (A) were grown to log phase and extracts were prepared. Samples were analyzed by immunoblot as indicated.
amino acids 465-399 are critical for maintaining the cell’s ability to grow when TORC1 activity is reduced. Interestingly, a similar effect is seen with caffeine between fragments B and C, suggesting that Tco89 may mediate the cellular response to rapamycin and caffeine in different ways. Although fascinating, this result is not entirely surprising given previous work that indicated rapamycin and caffeine affect TORC1 function disparately [320], and that caffeine may inhibit TORC1 in a Tco89-dependent fashion [62].

Finally, we explored whether the dramatic shift in spotting phenotypes observed between fragments C and D correlated with a decline in TORC1 activity. Cells from Figure 5-2A were grown to log phase, WCEs were prepared, and TORC1 signaling was assessed by blotting for phosphoS6. In Figure 5-2C, we demonstrated that indeed there is an almost complete loss of steady state TORC1 function from fragment C to fragment D, which correlates nicely with the significant increase in sensitivity to rapamycin and caffeine (Figure 5-2A and 5-2B). We had hoped to utilize these truncation mutants for further phenotypic evaluation, however given that our selectable marker was auxotrophic, and all of our processes of interest are highly responsive to nutrients, the necessity of growing cells on defined media to select for the plasmids led to confounding results (data not shown).

The Observed Cell Cycle Arrest in tco89Δ Upon TORC1 Limitation Is Not Attributable to Dysregulation of Reactive Oxygen Production

We next wondered whether tco89Δ’s dramatic sensitivity to TORC1 inhibitors could be partially alleviated by removal of an upstream negative regulator of TORC1. To assess this possibility, we deleted the gene encoding NPR3, a Gtr1 GTPase that suppresses TORC1 signaling. We found that loss of this negative regulator was not sufficient to overcome the observed rapamycin sensitivity, as tco89Δ npr3Δ grew just as poorly as tco89Δ (Figure 5-3A). This likely means that Npr3 inhibition of TORC1 occurs upstream of tco89Δ.

Given the reported nutrient utilization phenotypes of a tco89Δ [319], and considering that TORC1’s effect on lifespan has been suggested to occur, in part, through mediation of mitochondrial ROS signaling [321-325], we next examined the effect loss of Tco89 has on mitochondrial function. Previous findings demonstrated that in wild-type cells, the transition from log phase to stationary phase is marked by a dramatic increase in ROS levels [321]. Interestingly, tor1Δ displays increased basal levels of ROS, though there is a negligible effect on cellular ROS as this mutant transitions from log phase to stationary phase [321]. Early exposure to ROS in the tor1Δ is suggested to “toughen up” the cells, a phenomena known as hormesis [326]. The combination of hormesis and the reduction in stationary phase ROS has been hypothesized as one of the ways tor1Δ, and TORC1 suppression in general, contributes to an increase in lifespan.

We knew that in tco89Δ, nutrient limitation, TORC1 inhibition, or simply growing cells to saturation (late log phase) resulted in a permanent exit from the cell
Figure 5-3. Loss of Tco89 results in adaptive ROS response similar to that observed in tor1Δ.

A. Wild-type (WT), npr3Δ, tco89Δ and tco89Δ npr3Δ cells were grown to stationary phase, five-fold serially diluted, and spotted onto YPD and YPD + 10 nM rapamycin. Photos provided are representative of growth after 3 days.

B. WT and tco89Δ cells were grown to early log phase (OD~0.4) and mid stationary phase (OD~15). At both points, aliquots of cells were stained with DHE for 20 minutes followed by flow cytometry analysis.

C. WT, tco89Δ and their corresponding mitochondrial-deficient strains (denoted ρ0) were grown to log phase, mock treated or treated with 25 nM rapamycin for 5.5 hours, washed, and spotted onto YPD.
cycle [43, 49]. This led us to wonder what the ROS profile in a \textit{tco89Δ} would look like as the strain transitioned from log phase to stationary phase, and whether dysfunction in the regulation of ROS production could possibly explain these cell cycle defects. Unlike \textit{tor1Δ}, the \textit{tco89Δ} displayed no significant increase in log phase ROS, though it did have a significant reduction in stationary phase ROS when compared to the wild-type cells (Figure 5-3B). The nature of the difference between \textit{tor1Δ} and \textit{tco89Δ} is not readily apparent, though given that log phase and stationary phase \textit{tco89Δ} cells have nearly identical ROS levels, we can say that the observed cell cycle exit is not due to an inability to coordinate these ROS pathways.

Finally, we wondered whether compromising the mitochondrial genome (denoted \textit{ρ}) would have an effect on the normal growth of \textit{tco89Δ}, or its response to transient TORC1 inhibition. Wild-type, \textit{tco89Δ}, and their corresponding \textit{ρ} mutants were grown to log phase, mock treated or treated with rapamycin for 5.5 hours, washed and spotted onto YPD. The mock treated \textit{ρ} mutants do tend to grow slower than the paired controls. However there does not appear to be any TORC1-dependent difference, as the \textit{tco89Δ \textit{ρ}} mutant is equally as sensitive to transient rapamycin treatment as \textit{tco89Δ} (Figure 5-3C).

In total, this chapter represents the first structural assessment of the role of the Tco89 subunit within the TORC1 complex. Through construction of a series of truncation mutants, we identify the specific domain that is critical to allow cells to grow in the presence of TORC1 inhibition, and demonstrate that this domain is also critical for steady state TORC1 function. We report that the irreversible cell cycle arrest observed in nutrient deprived \textit{tco89Δ} cannot be explained solely through defects in ROS signaling as cells transition from log phase to stationary phase. We believe these findings and tools will inform future studies to wholly characterize Tco89, and to determine whether it has a functional mammalian counterpart.
CHAPTER 6.  DISCUSSION AND FUTURE DIRECTIONS

It is critical for eukaryotes, whether they are single-celled yeast or multicellular organisms, to rapidly adjust their growth and proliferative profiles in response to intracellular deficits or changes in their extracellular environment. Studies from a number of labs suggest a regulatory link exists between TORC1 and the epigenome, including work in which we characterized the TORC1-responsive acetylation of H3K56 [66]. Additionally, we know from prior studies that a correlation exists between TORC1 activity, histone acetylation, and HMGB chromatin binding [152]. At the outset of this study, we speculated that TORC1 signaling likely regulates other histone modifications besides H3K56ac, as it was demonstrated to mediate pan-H4 acetylation at the ribosomal protein genes [12], and that these modifications may contribute to anchoring HMGBs to chromatin.

TORC1 and Histone Acetylation

In Chapter 3, we significantly expanded our understanding of the upstream stimuli linking TORC1 to the control of histone acetylation, and we gained an appreciation of the breadth of TORC1-responsive histone modifications. Foundational studies in the field utilized pan-H3 and pan-H4 acetyl antibodies to identify gross acetylation loss in response to TORC1 inhibition [12, 13]. But here we characterized for the first time the TORC1-mediated acetylation of H3K18, H3K23 and H4K12 (Figure 3-1). The specificity we observed is quite interesting and suggests inhibition of TORC1 is not promoting a global decrease in histone acetylation, nor is it a massive non-specific effect due to loss of all transcription-coupled marks (H3K4me3 is intact).

One possible explanation could be that inhibition of TORC1 results in a shift in metabolic intermediate availability, including acetyl CoA and NAD+, which feed into the acetylation and deacetylation reactions respectively. However, we would expect that if this were the case, the effects would be more universally observed across a multitude of histone residues. Rather this hypoacetylation appears to be a specific, site-directed response to decreased TORC1 function, as low-level pharmacological inhibition for a short time (20 minutes) is sufficient to induce the effect. Considering the existing link between TORC1 and the post-translational modification of H2A in the DNA damage response [327], it would be fascinating to probe other acetylation states such as H2AK7, H2AK21, H2BK11, and H2BK16, to see whether TORC1-responsive acetylation exists on H2A or H2B as well. We believe it is likely that TORC1-dependent histone modifications extend beyond acetylation, possibly to acylation (sirtuin substrate), phosphorylation, methylation, sumoylation, neddylation and others. Incorporation of mass-spectrometry based histone proteomics would provide us a more complete understanding of the diversity of the histone post translational modifications downstream of TORC1.
TORC1 occupies a critical point in a pair of nutrient sensing axes. Amino acids and carbon both feed into the TORC1 signaling pathway, and each appears to do so, in part, through adaptive intracellular pH mechanisms [49, 80, 328]. Prior to this work, TORC1-responsive acetylation has been investigated exclusively by using the direct pharmacological TORC1 inhibitor, rapamycin. And while we also utilize rapamycin for this purpose, we extend our analyses to include several additional means of suppressing TORC1 activity. These stimuli are likely more physiologically relevant and thus, we examined their influence on our chromatin modifications of interest.

We provide striking evidence that not all TORC1 inhibition is equivalent at the level of acetylation, finding that nitrogen metabolism disruption (MSX), but not carbon limitation, led to decreased acetylation of a model TORC1 residue (Figure 3-2). The data presented argues against the previous claims that crosstalk between carbon metabolism and TORC1 signaling is responsible for our observed epigenetic effects [328, 329]. Instead, they suggest an interesting regulatory bifurcation through which cells may tailor their epigenome based on the specific nutrient they are lacking. There is likely a degree of overlap between nitrogen and carbon metabolism, as inhibition of TORC1 did not result in total ablation of our modifications of interest. Still, these findings illustrate that nitrogen signaling plays a vital and distinct role in the dynamic regulation of key acetylation sites. Additionally, they imply that signaling between vacuolar components (v-ATPase, EGO complex) and TORC1 is vital for the relay of environmental energy states to chromatin-based processes. Indeed a previous genetic screen of the yeast deletion collection found that a number of vacuole mutants display acetylation phenotypes [330]. We speculate that functions previously attributed to TORC1-mediated histone acetylation, including rDNA stability and regulation of RP gene expression [12, 13], are also nitrogen specific given that the need for ribosomes and anabolic flux is reduced under starvation conditions. However, because these studies only utilized rapamycin to inhibit TORC1, it is impossible to be sure without delving back into those questions using specific amino acid starvation or suppression of general nitrogen metabolism via MSX.

In Chapter 3 we also present findings demonstrating that TORC1-dependent histone acetylation is regulated by sirtuin histone deacetylases. This corroborates our previous observation that deletion of HST3 and HST4 in the tco89Δ background is sufficient to rescue H3K56ac [66]. The connection between TORC1 and the sirtuins makes sense considering how intimately each is tied to cellular energy states. TORC1 activity is most robust during times of nutrient abundance when cell growth and proliferation would be appropriate and advantageous, while sirtuins are most active when energy availability is limited (low NADH concentration, elevated NAD+/NADH ratio) [291]. The reciprocal arrangement between TORC1 and the sirtuins reported in yeast appears to be evolutionarily conserved, as mTORC1 suppression in metazoans promotes transcription of the SIRT4 gene [184].

Within our sirtuin results (Figure 3-10), we reported several previously unidentified, candidate substrates for each of the enzymes: Hst1 (H4K12ac), Hst2 (H3K18ac), Hst3 (H3K18ac, H4K12ac), Hst4 (H3K18ac, H3K23ac, H4K12ac) and Sir2
(H4K12ac). Looking over these acetyl sites, we recognized several that are downstream of sirtuins in higher order organisms as well, including H3K18ac (deacetylated by SIRT6 and SIRT7) and H3K56ac (deacetylated by SIRT6). SIRT6 regulation of H3K18ac was only recently identified, and was shown to occur at pericentric heterochromatin [237]. Hyperacetylation of H3K18ac in the absence of SIRT6 (which will also increase H3K56ac) leads to transcriptional activation of the otherwise silent pericentric chromatin, and accumulation of centromeric transcripts causes mitotic defects, genomic instability and cellular senescence. This is fascinating considering our data linking the yeast sirtuin Hst4, a regulator of H3K18ac, and the ability of tco89Δ cells to re-engage the cell cycle (or evade arrest entirely) in response to TORC1 inhibition. Additionally, the SIRT7-dependent regulation of H3K18ac has been reported to promote oncogenic transformation and maintain tumorigenicity by disabling transcription of tumor suppressor genes [240, 331, 332]. Notably, it was previously reported that overexpression of SIRT1 could complement loss of Sir2 in yeast [177].

We believe future complementation studies using vector-based human sirtuins in yeast deletion mutants could flesh out whether the human sirtuins are also responsive to TORC1, while highlighting which enzymes are most functionally conserved between humans and yeast. This would also provide significant evidence of mechanistic conservation of our described mechanism. A shortcoming of this portion is that to this point, all of the data linking TORC1 and specific acetylation states has been genetic in nature. Considering all the different pieces of evidence we have obtained, we are extremely confident that this observed phenomena is biologically real. Still, our stance would be significantly strengthened if we were to use biotinylated recombinant histones in *in vitro* deacetylation assays (such as the Fluor de Lys™ assay from Enzo Life Sciences [159]) to confirm that the sirtuins do in fact target these residues.

The PP6 Phosphatase Complex and the TORC1-Dependent “Acetylome”

Our data demonstrate that when ample nitrogen is available, TORC1 regulates sirtuin-dependent site-specific histone H3/H4 acetylation through the suppression of the Sit4/PP6 complex and subsequently, enhanced Hst4 protein levels. One of the most compelling parts of this work involves how PP6 activation triggers this increase in Hst4 expression. We first investigated whether *HST4* gene transcription is regulated through the Sit4-mediated NCR stress response by deleting the Sit4-responsive transcription factors Gln3 and Gat1. The rationale being that if Hst4 protein levels are tied to Gln3 and/or Gat1 function, deletion of these NCR components should result in a decrease in Hst4 protein and an increase in histone acetylation. It was clear however, that this was not the case. Loss of these transcriptional regulators did not have a positive effect on acetylation. Likewise, deletion of the cytoplasmic anchor that mediates their cytoplasmic localization upon nutrient stress did not promote a decrease in acetylation. We also find that TORC1 inhibition does not result in any increase in *HST4* mRNA expression, all together suggesting that the elevated Hst4 protein levels that occur in response to TORC1 inhibition occurs independent of *HST4* transcriptional regulation or changes to *HST4* mRNA stability. Instead, we report a mechanism in which Sit4 activation promotes a
rapid, cytoplasmic to nuclear redistribution of Hst4, resulting in protein stabilization and a site-specific decrease in histone acetylation. The most important take away is timing, as we demonstrate that maximal nuclear accumulation occurs within 20 minutes (Figure 3-16). Presumably, it is this population of Hst4 that promotes the immediate deacetylation observed upon acute rapamycin treatment. The subsequent increase in protein levels does not occur until some 40 minutes later (Figure 3-11), and we believe this stabilization sustains the hypoacetylation phenotype until TORC1 activity is restored.

In situations where we find a TORC1-dependent increase in Hst4 levels, we also observe a corresponding decrease in Hst3, which could suggest a regulatory balance exists between the amount of Hst3 and Hst4 in the cell. This possibility has already been hinted at in a work which demonstrated that the replication origin deficiencies observed in an hst3Δ cell could be overcome by expressing Hst4 under the control of the Hst3 promoter [333]. Still, it is currently unclear as to how Sit4-PP6 activation results in Hst4 nuclear accumulation (denoted by question marks in Figure 6-1). Our Phos-tag results (Figure 3-15) would suggest that this stabilization is not directly attributable to Sit4-mediated sirtuin phosphorylation. However, we have only addressed this hypothesis with the Phos-tag approach, as our attempts to incorporate pan-phosphorylation antibodies and phosphostains were unsuccessful (data not shown). As a consequence, given what is known about the turnover of Hst3, we cannot yet exclude the possibility that Sit4-dependent dephosphorylation of Hst3 or Hst4 does indeed regulate their function. Still, this leaves us to wonder about alternative explanations. Such as whether the phosphatase may coordinate sirtuin nuclear localization through regulation of importin (Srp1) and exportin (Xpo1) factors; the yeast carrier proteins responsible for actively chaperoning cargo proteins in and out of the nucleus. There is precedent for this as Hst2 shuttling is known to be regulated by Xpo1 [164]. Further, the import capacity of a mammalian ortholog of Srp1, importin α1, has been shown to be responsive to phosphorylation and acetylation [334].

Interestingly, it would appear that the identity of the Sit4-associated protein may confer an additional layer of specificity to the acetylation response, as we find that loss of Sap4 or Sap185 leads to a reduction in H3K18ac rapamycin sensitivity (Figure 3-6). Previous work examining rapamycin and zymocin sensitivity in yeast also identified dramatic phenotypic differences attributed to Sap association [100], though it is unclear what exactly the Saps contribute to these processes. Given the partial rescue observed in the sap4Δ and the sap185Δ, we speculate that these regulatory subunits are functioning at least somewhat redundantly to bridge the interaction between the Sit4 phosphatase and its downstream targets. Considering the high degree of conservation across this pathway, and that mammalian sirtuins are known to actively shuttle from the nucleus to the cytoplasm, we propose that future studies include pilot experiments asking whether exogenous human Sit4 (PPP6C) could complement Hst4 stability and localization in a sit4Δ cell. A similar approach could be conducted using the human Sap orthologs (PPP6R1/2/3). If it appears these mechanisms are indeed conserved, we could attempt to replicate these findings by monitoring acetylation in human cells with RNAi knockdown of PPP6C, PPP6R1/2/3, or the sirtuins which have been shown to shuttle intracellularly (SIRT1/2/3).
Figure 6-1. Proposed mechanism.
Summary of work presented in Chapter 3 as discussed in Chapter 6. Areas requiring further study are denoted by question marks. See text for more details.
Finally, it seems likely that TORC1 regulation of sirtuin function could contribute to changes in acetylation of non-histone substrates as well. The mammalian sirtuins, and particularly SIRT1, have been shown to target chromatin-modifying enzymes (p300, MOF, Tip60), as well as proteins involved in autophagy (FOXO1, FOXO3, LC3, Atg5/7/8), the stress-response (NF-κB, c-Myc, HIF-1α), metabolism (LKB1, PGC-1α) and DNA repair (Ku70, PARP1). Can we build on this information to define a TORC1-responsive acetylome to better understand how aberrant mTORC1 signaling promotes disease? Could some of mTORC1’s canonical functions (anabolism, autophagy, and ribosome biogenesis) be partially attributed to mTORC1-dependent sirtuin localization? In addition to the yeast orthologs of the proteins mentioned above, there are a few other yeast candidate factors we propose evaluating in future studies.

Spt7

Previous studies identified a replicative lifespan increase in mutants of the Gcn5-containing SAGA histone acetyltransferase complex [335]. This observed lifespan extension could implicate TORC1 in coordination of SAGA function, and the fact that this effect requires Sir2 suggests the possibility that TORC1-dependent sirtuin activity could feed into SAGA. The Pep4-dependent processing of the SAGA subunit, Spt7, determines whether SAGA exists as a holocomplex or a subcomplex (also known as SLIK/SALSA) lacking Spt8 [336]. Spt7 has been shown to possess a bromodomain whose chromatin binding is sensitive to histone acetylation [337], and Spt7 has itself been suggested to be acetylated [163].

We speculate that TORC1 may participate in regulating SAGA chromatin binding through coordination of H3 acetylation (Chapter 3). However, it is also possible that TORC1 may affect Spt7 acetylation via sirtuin stabilization to influence Spt7 processing, and SAGA composition or localization. It would be fascinating to utilize the previously described multi-epitope Spt7 strains [338] to assess TORC1 contributions to these SAGA dynamics. Further, we could immunoprecipitate Spt7 under same conditions and immunoblot to determine if its acetylation state is dependent on TORC1 activity. Either of these proposed mechanisms (histone acetylation dependent, direct effects on SAGA via Spt7) would enable TORC1 suppression to promote initial histone deacetylation through nuclear accumulation of Hst4, and also to feed back onto SAGA to prevent the incorporation of new histone acetyl marks. Together, these effects maintain a transcriptionally repressive chromatin state until environmental conditions improve.

Ifh1

Ifh1 is a coactivator of ribosomal protein gene transcription, and it is found at the RP promoters when environmental nutrient availability is sufficient to sustain growth. It is an essential gene that, when partially inactivated, results in an extension of lifespan marked by increased sensitivity to rapamycin and DNA damage. Gcn5 acetylates Ifh1 in a TORC1-responsive fashion, which allows for a RP transcriptional burst following
refeeding. Importantly, these Gcn5-dependent modifications are opposed by a subset of sirtuins. Together, this suggests the possibility that sirtuin localization/stabilization may communicate changes in TORC1 activity to ribosome biogenesis via Ifh1 acetylation or SAGA function (see above). If TORC1 regulates Ifh1 acetylation through a Sit4-sirtuin pathway, we would expect that loss of the phosphatase would render Ifh1 marks insensitive to rapamycin. Similarly, if the hypothesis is correct, Ifh1 acetylation should fluctuate with MSX or nicotinamide treatment as well.

**Mitochondrial proteins**

Lastly, we propose examining the acetylation state of mitochondrial proteins in response to TORC1 activity. We presented evidence in Chapter 3 that localization of Hst4 shifts toward a more nuclear distribution upon inactivation of TORC1. At the time we did not attempt to categorize where in the cytoplasm the mobilized Hst4 was coming from. However, we were inspired by a recent work that demonstrated Hst4 can localize to the mitochondria in a dynamic fashion and deacetylate mitoproteins [176], drawing parallels between yeast Hst4 and mammalian SIRT3 (see Table 1-2).

We speculate that when TORC1 is inhibited, mitochondrial Hst4 localizes to the nucleus. This means that not only does amino acid starvation promote deacetylation of nuclear proteins, but it also may result in an indirect increase in acetylation of mitochondrial proteins as a consequence of a depletion of mitochondrial-localized sirtuins. This could have a significant consequence on cellular metabolism, oxidative stress and mitochondrial efficiency. The possibility of a multi-organellar signaling web connecting the vacuole, the mitochondria, and the nucleus is tantalizing. Incorporating MitoTracker (Life Technologies) into our Hst4-9xMyc confocal studies (Figure 3-15), or immunoprecipitating mitochondrial proteins and evaluating whether they display TORC1-responsive acetylation, are comparatively quick and easy ways to determine whether the proposed connection would be worth pursuing. The aforementioned biotin study from Madsen et al. does provide us with a few candidates to work with, as they characterized the dynamic acetylation states of specific mitoproteins in the absence of Hst2, Hst4, or Sir2 [176]. We were able to use this data to determine which proteins are most highly responsive to Hst4 activity, and then stratify further by which targets’ acetylation seems to be specific for Hst4 (since we know only Hst4 is significantly relocating). There were a few hits that were particularly interesting and could warrant further study.

Asparagine synthetase displayed the greatest increase in acetylation in response to hst4Δ (30 fold), which would make sense if the TORC1-regulation of sirtuins promotes amino acid biosynthesis to attempt to overcome starvation. Fumarate reductase was also an interesting find as it functions in the electron transport chain, meaning that affecting its acetylation could result in changes in ATP production from mitochondria. And finally, isocitrate dehydrogenase is a possible candidate as well, as its p-value was very high and it plays a critical role in the TCA cycle. TORC1-regulated acetylation of either fumarate reductase or isocitrate dehydrogenase would suggest a linkage between environmental nutrient status and cellular bioenergetics at the mitochondria anchored by TORC1.
TORC1-Dependent Histone Acetylation and Anabolic Gene Transcription

TORC1 signaling is known to promote transcription of an array of anabolic genes involved in cellular growth and proliferation. Inactivation of TORC1 during starvation leads to reduced expression of these genes. However, the extent to which TORC1-responsive histone acetylation contributes to these transcriptional dynamics remains unclear. To date, the most well-defined links between TORC1 and anabolic gene transcription are Sch9-dependent, yet we know that the histone acetylation response occurs through the Tap42-associated phosphatases, specifically PP6. We wondered then whether deleting components of our signaling pathway would result in changes to RP gene expression.

Somewhat surprisingly, in a TORC1 mutant \( (tco89\Delta) \) where we have identified global acetylation defects, mRNA levels of select ribosomal protein genes are unaffected. Chen et al. provide a possible explanation for this, as they report that TORC1 regulation of the RP genes occurs in parallel with PKA \([339]\). This type of dual input allows for proper coordination of ribosome biogenesis with both carbon and amino acid availability, but also suggests that in \( tco89\Delta \), the low-level TORC1 activity (Figure B-1) paired with functional PKA may be sufficient to maintain RP gene expression. In our previous work characterizing TORC1-dependent rDNA transcription, we utilized H3K56A mutants, which would theoretically ablate all H3K56 acetylation in the cell. Therefore, another possible explanation for the lack of effect on RP gene expression could be that the low level of basal TORC1 activity retained in \( tco89\Delta \) may be able to sustain local acetylation, and as a consequence transcription, despite the overwhelming global changes. This hypothesis is supported by the fact that the cells show no obvious growth deficiency under steady state conditions.

It is important to remember that TORC1’s transcriptional regulation reaches beyond just RP genes, so it is possible that other genes will be responsive to the reduced histone acetylation described here. Future studies incorporating ChIP-seq technology (identify genes with TORC1-responsive acetylation) and RNA-seq (quantify changes in gene expression in response to TORC1 inhibition) will be the foundation for examining how these modifications influence the transcriptional process. These data sets can be overlaid to identify genes whose acetylation patterns are TORC1-dependent and correlate with gene expression. Single gene ChIP and RT-qPCR analysis would confirm these findings, while also determining where on the gene (promoter/body) these modifications are occurring. Altered histone lysine acetylation may contribute to gene expression generally, by loosening the DNA-nucleosome contacts and enabling chromatin decondensation. But acetylation changes may also alter the docking of chromatin modifying complexes containing bromodomains or YEATS-domains \([340, 341]\). Gaining a greater understanding of how the chromatin association of these ancillary factors changes in response to TORC1 activity will be critical to defining how environmental nutrient availability influence anabolism at the level of transcription. Altogether, this information would provide significant insight into how these TORC1-responsive histone acetylation states affect chromatin-based processes.
Interplay between Histone Acetylation and Sensitivity to TORC1 Inhibition

tco89Δ cells are acutely sensitive to rapamycin and arsenic trioxide. Importantly, while these compounds are often grouped together as “TORC1 inhibitors”, the cellular response they elicit, and the way in which these signals are relayed throughout the cell, can vary significantly [314]. The effect of rapamycin on yeast TORC1 is well understood. FK506-associated rapamycin directly binds the Tor1 kinase via its FKBP-rapamycin binding domain. Short term exposure results in transient G1-S cell cycle arrest, while long term TORC1 inhibition results in a G0 (or quiescence) response which proves inescapable if TORC1 function is compromised (i.e. tco89Δ). Arsenic trioxide’s effect on TORC1 is more unclear, though the majority of its phenotypes appear to be Sch9-dependent [313]. The metalloid has been reported to promote a G2-M cell cycle arrest in cell culture models [342].

Interestingly, we demonstrate that the TORC1-PP6-sirtuin cascade delineated in Chapter 3 may contribute to cell-cycle re-entry following certain types of TORC1 stress, as tco89Δ hst3Δ and tco89Δ hst4Δ mutants are able to escape their reported arrests and grow similar to wild-type cells on both rapamycin and arsenic. We note that there are likely many other signaling molecules feeding into these processes, as tco89Δ hst3Δ or tco89Δ hst4Δ mutants are still sensitive to higher doses of rapamycin (10 nM, Figure 3-18, top right panel). There is a precedent for Tap42-associated phosphatases regulating the cell cycle, as it was previously shown that the nitrogen responsive, Rim15-dependent phosphorylation of PP2A plays a critical role in cell entry and exit from quiescence [343]. We propose that sirtuin stabilization downstream of TORC1 inhibition may reinforce the cell-cycle exit observed in tco89Δ cells exposed to arsenic or rapamycin, in part through chromatin deacetylation. Further, we believe that the deletion of HST3 or HST4 in the tco89Δ background enables re-entry by promoting a hyperacetylated, transcriptionally permissive chromatin structure, devoid of barriers to the induction of genes required to exit cell-cycle arrest. Support for such a mechanism exists, as a similar observation was recently described in which carbon-responsive histone acetylation regulates transcription of the CLN3 cyclin to mediate reentry into the cell-cycle following glucose starvation [151]. A second explanation for the phenotypic rescue observed in the tco89Δ hst3Δ and tco89Δ hst4Δ is that, rather than loss of the sirtuins promoting exit from the transient cell-cycle arrest, the strains may simply be unable to initiate the arrest without these sirtuins. Previous reports have demonstrated that tco89Δ cells are also sensitive to the DNA damaging agent hydroxyurea [57], though the high throughput nature of the study makes it unclear as to whether treatment induces a cell cycle arrest similar to rapamycin, or if it promotes cell death. Similar to the findings with rapamycin and arsenic, the tco89Δ hst3Δ and tco89Δ hst4Δ strains show little sensitivity to hydroxyurea, which we hypothesize may be explained by restoration of H3K56ac, a chromatin mark essential for DNA repair. Indeed it has been previously shown that mimicking H3K56ac promotes resistance to DNA damaging agents [153]. In all, we find that preventing sirtuin activation downstream of TORC1 inhibition is sufficient to rescue sensitivity to rapamycin, arsenic trioxide and hydroxyurea, though likely through distinct mechanisms.
Deletion of *SIT4*, the phosphatase identified as a regulator of sirtuin localization and stabilization, was sufficient to rescue *tco89Δ*’s growth on hydroxyurea and arsenic oxide. Unexpectedly though, it had no effect on rapamycin sensitivity. Resistance to hydroxyurea is likely due once again to H3K56ac, as was alluded to above. A previous work demonstrated that Sit4’s function in response to rapamycin is dependent on the identity of the associated Sap protein, which certainly implies the possibility of context-specific functions [100]. To our knowledge, nobody has ever looked at how various TORC1 stressors affect Sit4-Sap interactions, but if arsenic and rapamycin have distinct effects on these dynamics, it could explain the observed plating phenotypes. Another possible explanation is that the Sit4 phosphatase, which is known to exist outside of Tap42, has both positive and negative functions in TORC1-dependent cell growth and the necessity of each depends on the nature of the stress. We speculate that one such positive function may be a feedback signal from the Tap42-phosphatases, or the downstream sirtuins, to Sch9. Indeed a similar mechanism has been identified in mammals, albeit for a different downstream mTORC1 effector, as SIRT1 activation in response to caloric restriction regulates the acetylation, and subsequent TORC1-dependent phosphorylation, of S6K1 (Ypk3 in yeast) [344-347]. Sch9 activity is known to be responsive to NAD⁺ homeostasis [348] (an essential co-factor for sirtuins), acetylation of its upstream regulator Sip2 [349], as well as direct phosphorylation by TORC1 [80]. Considering aforementioned evidence, we wonder whether in response to starvation, the activation of the Tap42-associated PP6 complex, and subsequent stabilization of sirtuins, may feedback onto Sch9 to silence any TORC1-independent activity that may arise while nutrients are limiting. If this were the case, in our *tco89Δ sit4Δ* strain, in addition to preventing the nuclear accumulation and stabilization of the sirtuins (reversing the hypoacetylation response), we are also allowing for low-level TORC1-independent activation of Sch9. This could enable these mutants to grow on arsenic trioxide since the majority of arsenic effects are Sch9 specific. However the reason why these cells do not grow on rapamycin may be due to the lack of signal continuity, as a cell’s ability to grow in the presence of rapamycin requires coordination of Sch9 and Tap42-associated phosphatases. Each of these effectors are known to regulate critical responses downstream of starvation.

In summary, the findings in Chapter 3 identify a novel signaling mechanism through which amino acid availability is sensed by TORC1 and relayed to chromatin in two parts. The initial PP6-dependent nuclear accumulation of Hst4 prompts rapid changes in site-specific acetylation of H3 and H4. The subsequent increase in Hst4 protein stability suggests that nuclear localization may shield Hst4 from proteasomal turnover. We believe that this influx of Hst4 sustains the hypoacetylation response until the environment is permissive for growth. Coordination of these dynamics appears to play a vital role in at least a subset of TORC1’s biological functions.

**Epigenetic Dysfunction and Cellular Transformation**

It has been widely reported that a vast array of cancers display aberrant mTORC1 function. This may occur in response to loss of function in the tumor suppressor PTEN,
hyperactivation of PI3K, deletion of TSC1/2, or other genetic lesions that act to impair normal mTORC1 regulation. Accordingly, a sizable arsenal of mTORC1 inhibitors (“rapalogs”) have been developed and paired with just about every therapeutic imaginable in clinical trials. In addition to mTORC1 dysfunction, many tumors also display altered cellular metabolism and increased nitrogen requirements [350]. These changes would likely feed into sustaining mTORC1 activity and involve the amino acid sensing machinery at the lysosome. With this in mind, a new approach that is gaining traction involves targeting v-ATPase function to overcome drug resistance and prevent metastasis in a subset of cancers, including breast, non-small-cell lung, leukemia and sarcoma [351-357]. We speculate that at least some of the benefit observed from inhibition of the v-ATPase results from the corresponding reduction in mTORC1 function. However our data also indicates that mTORC1-responsive acetylation is strictly downstream of amino acids, meaning that inhibiting the v-ATPase, rather than mTORC1, may produce discernible differences in the downstream cellular phenotype.

Indeed, a recent publication found that overexpression of the E2F1 transcription factor results in stimulation of v-ATPase activity, lysosomal reorganization, mTORC1 activation and autophagic inhibition [358]. Interestingly however, these functions do not overlap substantially. Activation of mTORC1 involves altered lysosomal trafficking, while the activation of v-ATPase activity involves promoting the association of the V0 and V1 subunits [358]. The authors speculate that pharmacological inhibition of the v-ATPase may be beneficial in curbing metastasis in tumors overexpressing E2F1. This study beautifully illustrates how fully understanding a signaling pathway enables a more targeted therapeutic approach.

Considering what we now know about TORC1-mediated histone acetylation, and given that these modifications have been tied to transcription, chromatin remodeling, bromodomain docking, DNA repair, cell cycle progression and genomic stability, it is clear that epigenetic dysregulation downstream of hyperactive mTORC1 could play a significant role in disease pathogenesis. Such a relationship would explain the efficacy of combinatorial therapies pairing mTORC1 inhibitors with sirtuin activators [359-361]. It would be interesting to compare the epigenetic response elicited by rapamycin, bafilomycin A1 (v-ATPase inhibitor), or a combination of the two. We believe this area of study deserves considerable attention, as it would provide significant insight into downstream consequences of mTORC1 dysfunction while also illuminating a poorly understood molecular mechanism of cancer progression.

**TORC1-Dependent Acetylation Does Not Contribute to HMGB Chromatin Binding**

In Chapter 4, we investigated whether the TORC1-PP6-Hst4 cascade described in Chapter 3 contributed to the seemingly TORC1-dependent chromatin association of HMGB proteins. Previous works demonstrated that H3K36 and H3K37, on the N-terminal tail of histone H3, were critical for HMGB chromatin binding [252, 253]. We also knew that disruption of this site in yeast (H3K37A) paired with TORC1 inhibition led to dramatic HMGB (Nhp10) displacement and cell death [152]. We confirmed here
that this biological response also occurs with other HMGBs, as Nhp6a shuttles to the cytoplasm in response to rapamycin in the H3K37A strain, but not in the H3WT or H3K37R (restores protein-protein interactions) strains. This movement precedes the observed apoptotic and necrotic cell death, and similar timing was described for Nhp10 [152]. To this point, the behavior of Nhp6a and Nhp10 in response to H3K37 mutation and TORC1 inhibition appear to mirror one and other.

We hypothesized that one reason TORC1 inhibition disrupts the chromatin binding of HMGBs is that the corresponding loss of acetylation, described in Chapter 3, may destabilize the association between HMGBs and the histone tail. Surprisingly though, combining H3K37A with hst4Δ or sap4Δ was not sufficient to suppress the HMG displacement or the apoptotic/necrotic cell death. We believe this is explainable by the fact that neither of these deletions completely restore acetylation under TORC1-suppressive conditions (Figures 3-6, 3-10). Unfortunately, we were unable to create an H3K37A sit4Δ mutant, which is the combination which likely would have been the most promising given that acetylation in a sit4Δ is almost completely irresponsive to TORC1 (Figure 3-5). It is possible that if we were to pre-treat H3K37A with nicotinamide prior to rapamycin exposure, we may see a reduction in HMG relocalization and/or cell death. We could pursue creating an H3K37A hst3Δ hst4Δ as well.

An important note to discuss is that until recently, HMGB1 nuclear release in mammals was believed to occur as a consequence of necrotic cell death. Once in the extracellular space, these proteins would function as signaling molecules to stimulate macrophage recruitment to clear the necrotic cells [251]. However, our timing experiments demonstrate that HMGB displacement in yeast occurs prior to induction of apoptosis and necrosis. This result leads us to propose that the nuclear to cytoplasmic movement of HMGs could be a contributing cause, rather than an effect, of cell death. With this new paradigm in mind, there are suddenly many new areas of study, including determining how the HMGs are inducing cell death (next section), and evaluating other potential intracellular signaling functions (e.g. bioenergetics, metabolism [255]) these molecules may possess. We can now begin to visualize a complex intracellular signaling web, centered on TORC1, which coordinates communication between the vacuole, the nucleus and the mitochondria to affect cell viability and lifespan.

One of the weaknesses of this section is that we do not provide unequivocal mechanistic evidence that the HMGBs are binding H3K37. Such experimental evidence could likely be achieved using recombinant wild-type or H3K37A containing nucleosomes and in vitro binding assays. Additionally, we do not understand yet where the HMGs relocalize to following their exit from the nucleus, although this is an area we are currently pursuing. We propose future studies examining how cells respond to constitutively cytoplasmic/nuclear versions of these HMGs to directly ask whether their altered subcellular distribution is causing the cell death observed in the rapamycin treated H3K37A cells. It would also be fascinating to pursue defining how decreased TORC1 signaling synergizes with H3K37A to cause selective cytoplasmic localization of specific HMGBs. We have not completely ruled out the contribution of TORC1-dependent chromatin modifications, though it seems equally plausible that localization of the
HMGBs may be mediated via direct modification (TORC1-dependent phosphorylation, sirtuin-dependent deacetylation, etc.); a phenomena that has already been reported in metazoan cells [362].

**Cells with Aberrant HMG Localization Undergo Massive Cell Death Characterized by Vacuolar Dysfunction and Hyperactive TORC1**

Despite finding that the TORC1-dependent histone acetylation marks likely do not contribute directly to the association of HMGBs and the H3 N-terminal tail, we were still very interested in characterizing the cell death that appears to be triggered in response to their nuclear displacement. After all, these dynamics proved capable of turning low levels of rapamycin from a cytostatic agent to a cytotoxic agent. The potential therapeutic benefit of targeting the chromatin association of HMGBs was apparent, and served as a driving factor for the inquiries that followed.

We first demonstrated that the cell death response triggered by HMGB dislodgement is preceded by significant acidification of the vacuole (Figure 4-3). This was most clearly observable in rapamycin treated H3K37A cells, however there was an approximate two-fold increase in CFDA staining of mock treated H3K37A cells compared to the wild type control. A similar response was observed in H3WT cells expressing exogenous Nhp6a and Hmo1 from a plasmid. We subsequently found that mock treated H3K37A cells, and the Nhp6a/Hmo1-expressing H3WT cells, also display a somewhat surprising increase in TORC1 activity. It is clear this is an HMGB-dependent response, as the H3K37A nhp6aΔ and the H3K37A nhp10Δ do not display substantially increased TORC1 function. The idea that aberrant vacuolar pH and elevated TORC1 signaling contributes to induction of cell death is supported by the fact that buffering the growth media was sufficient to reverse sensitivity to rapamycin (Figure 4-4).

We speculate that loss of vacuolar membrane integrity, leading to release of hydrolases/proteases and cellular acidification, may contribute to this HMGB-triggered programmed cell death. With the above concepts in mind, we propose that one possible destination for these displaced HMGBs may be the vacuole. There is, in fact, precedent for this concept. Mammalian inflammatory cells actively secrete HMGB1, and this process involves HMGB translocation from the nucleus to the lysosome in response to its acetylation [363, 364]. This intracellular shuttling is not limited to inflammatory cells though, as HMGB1 has also been shown to relocalize from the nucleus to the lysosome in the human peritoneal mesothelial cell line (HMrSV5), particularly in response to the availability of lipopolysaccharides [365]. These parallels provide support for the possibility that displaced yeast HMGBs are shuttling to the vacuole. This hypothesis is readily testable through co-localization studies incorporating fluorescent HMGB tags and vacuolar stains (FM4-64). Conversely, we could attempt to co-immunoprecipitate vacuole surface proteins and HMGBs. It is important to note that HMGB1 movement in mammals appears to be tied more to the secretory nature, rather than the pH, of the lysosome. However whether these functions are truly mutually exclusive remains to be seen.
If we assume for a moment that the HMGBs are functioning as signaling molecules as they move from chromatin to the vacuole, we are still left to wonder what exactly they are doing to promote vacuole acidification and TORC1 function. One consideration is that the activation of TORC1 could simply be a physiological response to HMGB-mediated pH changes, which likely occur through modulation of the v-ATPase. We believe that fluctuations in pH, to an extent, may optimize conditions for the vacuolar proteases leading to a more active enzymatic compartment, increased protein breakdown and nitrogen availability, and enhanced TORC1 function. And while plausible, this hypothesis would seem to contradict work from Hughes et al. which demonstrated that as cells replicatively age, increased TORC1 signaling results in a more basic vacuolar pH [366]. This increase in pH, which can be reversed by inhibiting TOR, PKA or Sch9, contributes to cellular aging and mitochondrial dysfunction as a result of defective amino acid storage. We note that Hughes is presenting this data in a different model of aging (replicative vs. chronological), however the link between TORC1 and vacuolar pH is striking. Considering this, we propose an alternative explanation. The observed increase in TORC1 signaling may be a compensatory mechanism to prevent the apoptosis and necrosis that occurs as a result of HMGB displacement. This concept would be consistent with our results which demonstrate that buffering the growth media partially suppresses the cell death phenotype of H3K37A mutants treated with rapamycin. This would also be supported by the fact that H3K37A cells grow very much like wild-type under steady state conditions, despite vacuole morphological differences and modest HMGB displacement.

If HMGB release from chromatin proves to be a cell-death initiation signal in mammalian cells like it appears to be in yeast, it would certainly be an attractive pharmaceutical target. Displacement of HMGBs at low levels appears to be tolerable, but when paired with low-dose rapamycin, it initiates a cell death response. This observation suggests that if HMGB1 chromatin binding could be interrupted, it may allow for administration of reduced doses of rapamycin, which could hopefully circumvent some of the most compromising side effects.

Mapping the Functional Domains of Tco89

In Chapter 5, we made significant strides toward understanding the yeast TORC1 subunit, Tco89. The severe rapamycin sensitivity in tco89Δ cells is marked by a permanent exit from the cell cycle, as was discussed previously [43], and it is our hope that a more complete understanding of the subunit’s role in the complex will lead to the identification of a mammalian ortholog. Existence of such an ortholog seems likely given that every other yeast TORC1 component has a mammalian counterpart. The mammalian equivalent of Tco89 would be an attractive therapeutic target to sensitize cells with hyper mTORC1 function to TORC1 inhibitors.

Using vectors expressing the different Tco89 fragments proved challenging when mapping the region required for particular TORC1-dependent functions. This was due to the need to culture the cells in nutrient-defined media to select for the plasmids. The fact
that TORC1 activity is so heavily impacted by availability of nutrients means that many of our phenotypes are not nearly as pronounced in synthetic complete media as they are in nutrient rich media. This makes observing differences, and attributing them to particular protein fragments, quite arduous. If these obstacles could be overcome, by tweaking media conditions or integrating our mutants into the genomic locus, there are a number of very interesting studies that could be conducted. The most straightforward of which involve utilizing our different fragments to map Tco89’s structural and functional contributions to TORC1. We could use co-immunoprecipitation to assess which domain is required for Tco89 incorporation into TORC1, as well as to investigate how Tco89 affects TORC1 complex stability by using Kog1 association with Lst8 as a readout. We have already mapped which portion is critical for regulating TORC1 function (via pS6 blot) and growth on rapamycin (Figure 5-2), and it would be interesting to follow up and ask whether this same region (demarcated between fragments C and D) is involved in coordinating TORC1-dependent histone modifications. Notably, an earlier study utilizing much larger Tco89 fragments reported that residues 799-388 were responsible for interacting with Vac8 to promote the turnover of non-preferred carbon utilization enzymes [62]. This overlaps with our region of interest (532-399), and could provide insight as to how Tco89 coordinates the TORC1-dependent nutrient stress response.

We are enthusiastic about the identification of this minimal portion of Tco89 as we believe it can enlighten us to what its true function is, while also aiding in determining which downstream proteins are participating in this diverse signal relay system. Immunoprecipitation of a few different fragments (i.e. one that does rescue on rapamycin compared to one that does not) paired with mass spectrometric analysis could be incredibly powerful, enabling us to identify the physical interactions necessary for these phenotypes. Likely hits would include members of the TORC1 complex and EGO complex, but we speculate there are additional, yet to be determined binding partners of significant biological relevance.

tco89Δ mutants growth arrest at the G1-S boundary and enter a permanent quiescence-like state (yet remain viable) when exposed to rapamycin, and we would like to understand how this response is initiated and sustained. We first wondered whether the cell cycle defect could be explained by an inability to manage ROS production as metabolic requirements shifted. The tor1Δ mutant is known to decrease TORC1 activity and extend lifespan. It displays a distinct increase in log phase basal ROS but a significant reduction (compared to wild-type) in stationary phase ROS. These effects on reactive oxygen have been identified as potential explanations for the observed increase in lifespan of TORC1 mutants, which led us to investigate whether tco89Δ was deficient in these mitochondrial-based processes. Our data demonstrate that unlike tor1Δ, tco89Δ does not undergo a significant increase in log phase ROS. Though both mutants share a significant reduction in stationary phase ROS compared to the wild-type. It is currently unclear what is occurring in the tco89Δ strain, as it appears that ROS levels have been completely uncoupled from these metabolically distinct stages of growth. We speculate that deregulation of sirtuin-dependent acetylation of mitochondrial proteins, as discussed earlier in this chapter, may contribute to the relatively stagnant ROS production in
Looking ahead, we are interested in investigating whether cellular growth and proliferation is sensitive to nutrients throughout the cell cycle, or if there is a defined window of time to arrest, after which the cell is committed to division regardless of nutrient availability. If we used α-factor (G1) and nocodazole (G2-M) to arrest cells, then released them into media containing rapamycin and analyzed their cell cycle profile via flow cytometry, we could begin to understand this TORC1-dependent regulatory signal. For example, following α-factor arrest, if tco89Δ cells exposed to rapamycin pass through S-phase and G2-M to finish their current cell division, it would suggest a brief window between mitosis and G1 at which cells assess their environmental conditions. If true, we would expect that cells arrested with nocodazole and released into rapamycin would complete mitosis and then enter G0.

In terms of sustaining the arrest, one possible explanation is that Tco89 coordinates the dynamic association of Rho1 and Tap42 to TORC1. This intricate relationship is known to regulate the stress response [50]. In the absence of Tco89, cells grow normally under steady state conditions, but we speculate that once the stress response is initiated (i.e. rapamycin), it cannot be turned off. This leads to the permanent cell cycle arrest, despite cells retaining viability. This could be studied by labeling and co-immunoprecipitating Kog1 and Rho1, and Kog1 and Tap42 in the absence and presence of Tco89. We could then ask whether disruption of the Rho1 stress response prevents rapamycin effects on acetylation. Finally, we could examine how the sirtuins fit into all of these functions since we know deletion of HST3 and HST4 is sufficient to promote growth on low-level rapamycin.

We acknowledge there is still considerable work to be done, but the potential of this project excites us. Undoubtedly, with persistence this avenue will prove fruitful. The trials outlined here have equipped our lab with a unique set of tools and information that we believe will soon lead us to the most comprehensive mechanistic and structural understanding of Tco89 to date.

**Closing Remarks**

It is becoming increasingly clear that the pathologies attributed to mTORC1 dysfunction, including metabolic disorders, cancer, and cardiovascular disease, likely possess a degree of epigenetic deregulation that far exceeds what was previously known. While this dissertation focused on a single post-translational modification, on a defined series of histone substrates, there are almost certainly many more TORC1-dependent histone post-translational modifications that have yet to be discovered. We have speculated on a few potential non-histone acetylation targets earlier in this chapter as well (Ifh1, Spt7, mitochondrial proteins). Given the involvement of PP6, a phosphatase known to regulate a number of downstream TORC1 effectors, there is a likelihood that TORC1...
activity could be translated into any number of epigenetic modifications beyond just acetylation, including methylation, phosphorylation, and ubiquitination.

The scientific funding and publishing bodies in this country have embraced high-throughput sequencing techniques, which are costly, laborious to interpret for non-bioinformaticians, and the results of which are often difficult to independently replicate. These technologies are immensely powerful, and they have led to some of the most compelling evidence of an epigenetic component to cancer; somatic mutations leading to an H3K27M substitution that drives gliomagenesis [367]. But the work presented in this dissertation illustrates how molecular biology is still a critical piece of the puzzle. There are reasons why combinatorial therapeutic approaches work but often times in the world of chemical screening and mouse modeling, the actual biology gets lost. If we understand how a signaling mechanism works under physiologically normal conditions, we know where to look when things begin to go awry.

It has truly been an honor working in such an elite, dynamic, rapidly expanding field with fantastic colleagues over the past five years. I look forward to seeing where the epigenetic community goes in the months and years to come.
LIST OF REFERENCES


## APPENDIX A. SUPPLEMENTAL TABLES

### Table A-1. List of strains used in this study.

<table>
<thead>
<tr>
<th>Strain</th>
<th>Genotype</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>BY4741</td>
<td>MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0</td>
<td>OPEN Bio</td>
</tr>
<tr>
<td>gat1Δ</td>
<td>BY4741; gat1Δ::KanMX</td>
<td>OPEN Bio</td>
</tr>
<tr>
<td>gln3 Δ</td>
<td>BY4741; gln3Δ::KanMX</td>
<td>OPEN Bio</td>
</tr>
<tr>
<td>hda1Δ</td>
<td>BY4741; hda1Δ::KanMX</td>
<td>OPEN Bio</td>
</tr>
<tr>
<td>npr3Δ</td>
<td>BY4741; npr3Δ::KanMX</td>
<td>OPEN Bio</td>
</tr>
<tr>
<td>ppg1Δ</td>
<td>BY4741; ppg1Δ::KanMX</td>
<td>OPEN Bio</td>
</tr>
<tr>
<td>pph3Δ</td>
<td>BY4741; pph3Δ::KanMX</td>
<td>OPEN Bio</td>
</tr>
<tr>
<td>rpd3Δ</td>
<td>BY4741; rpd3Δ::KanMX</td>
<td>OPEN Bio</td>
</tr>
<tr>
<td>sap155Δ</td>
<td>BY4741; sap155Δ::KanMX</td>
<td>OPEN Bio</td>
</tr>
<tr>
<td>sap185Δ</td>
<td>BY4741; sap185Δ::KanMX</td>
<td>OPEN Bio</td>
</tr>
<tr>
<td>sap190Δ</td>
<td>BY4741; sap190Δ::KanMX</td>
<td>OPEN Bio</td>
</tr>
<tr>
<td>sap4Δ</td>
<td>BY4741; sap4Δ::KanMX</td>
<td>OPEN Bio</td>
</tr>
<tr>
<td>sch9Δ</td>
<td>BY4741; sch9Δ::KanMX</td>
<td>OPEN Bio</td>
</tr>
<tr>
<td>sit4Δ</td>
<td>BY4741; sit4Δ::KanMX</td>
<td>OPEN Bio</td>
</tr>
<tr>
<td>tco89Δ</td>
<td>BY4741; tco89Δ::KanMX</td>
<td>OPEN Bio</td>
</tr>
<tr>
<td>tpd3Δ</td>
<td>BY4741; tpd3Δ::KanMX</td>
<td>OPEN Bio</td>
</tr>
<tr>
<td>ure2Δ</td>
<td>BY4741; ure2Δ::KanMX</td>
<td>OPEN Bio</td>
</tr>
<tr>
<td>H3G34A</td>
<td>MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]-ura3Δ</td>
<td>[315]</td>
</tr>
<tr>
<td>H3V35A</td>
<td>MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]-ura3Δ</td>
<td>[315]</td>
</tr>
<tr>
<td>H3K36A</td>
<td>MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]-ura3Δ</td>
<td>[315]</td>
</tr>
<tr>
<td>H3K37A</td>
<td>MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]-ura3Δ</td>
<td>[315]</td>
</tr>
<tr>
<td>H3K37Q</td>
<td>MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]-ura3Δ</td>
<td>[315]</td>
</tr>
<tr>
<td>H3K37R</td>
<td>MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]-ura3Δ</td>
<td>[315]</td>
</tr>
<tr>
<td>H3P38A</td>
<td>MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]-ura3Δ</td>
<td>[315]</td>
</tr>
<tr>
<td>H3H39A</td>
<td>MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]-ura3Δ</td>
<td>[315]</td>
</tr>
<tr>
<td>H3R40A</td>
<td>MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]-ura3Δ</td>
<td>[315]</td>
</tr>
<tr>
<td>Strain</td>
<td>Genotype</td>
<td>Source</td>
</tr>
<tr>
<td>---------</td>
<td>---------------------------------------------------------------------------</td>
<td>--------</td>
</tr>
<tr>
<td>H3WT</td>
<td>MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 can1::MFAP1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]-ura3Δ H3WT</td>
<td>[315]</td>
</tr>
<tr>
<td>YNL387</td>
<td>MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::KanMX hst3Δ::NAT</td>
<td>[66]</td>
</tr>
<tr>
<td>YNL389</td>
<td>MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::KanMX hst4Δ::NAT</td>
<td>[66]</td>
</tr>
<tr>
<td>Y3032</td>
<td>W303-1A tap42Δ::HIS3 pRS415-tap42-11</td>
<td>[309]</td>
</tr>
<tr>
<td>Y3033</td>
<td>W303-1A tap42Δ::HIS3 pRS414-TAP42</td>
<td>[309]</td>
</tr>
<tr>
<td>Y3034</td>
<td>W303-1A tap42Δ::HIS3 pRS414-tap42-106</td>
<td>[309]</td>
</tr>
<tr>
<td>Y3035</td>
<td>W303-1A tap42Δ::HIS3 pRS414-tap42-109</td>
<td>[309]</td>
</tr>
<tr>
<td>YNL251</td>
<td>MATa his3Δ11 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Sch9-6xHA::NAT</td>
<td>[304]</td>
</tr>
<tr>
<td>YNL487</td>
<td>MATa his3Δ11 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::NAT</td>
<td>[304]</td>
</tr>
<tr>
<td>YNL502</td>
<td>MATa his3Δ11 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::NAT rpt3Δ::KanMX</td>
<td>[304]</td>
</tr>
<tr>
<td>YNL516</td>
<td>MATa his3Δ11 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::NAT hst1Δ::KanMX</td>
<td>[304]</td>
</tr>
<tr>
<td>YNL517</td>
<td>MATa his3Δ11 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::NAT sir2Δ::KanMX</td>
<td>[304]</td>
</tr>
<tr>
<td>YNL519</td>
<td>MATa his3Δ11 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::NAT hst2Δ::KanMX</td>
<td>[304]</td>
</tr>
<tr>
<td>YNL541</td>
<td>MATa his3Δ11 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::HphNT1 pnc1Δ::KanMX</td>
<td>[304]</td>
</tr>
<tr>
<td>YNL564</td>
<td>MATa his3Δ11 leu2Δ0 met15Δ0 ura3Δ0 BY4741 ρ-</td>
<td>[304]</td>
</tr>
<tr>
<td>YNL566</td>
<td>MATa his3Δ11 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::KanMX ρ-</td>
<td>[304]</td>
</tr>
<tr>
<td>YNL583</td>
<td>MATa his3Δ11 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::NAT npr3Δ::KanMX</td>
<td>[304]</td>
</tr>
<tr>
<td>YNL612</td>
<td>MATa his3Δ11 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Hst4-9xMyc::KanMX</td>
<td>[304]</td>
</tr>
<tr>
<td>YNL614</td>
<td>MATa his3Δ11 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::NAT Hst4-9xMyc::KanMX</td>
<td>[304]</td>
</tr>
<tr>
<td>YNL622</td>
<td>MATa his3Δ11 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::NAT sir4Δ::KanMX</td>
<td>[304]</td>
</tr>
<tr>
<td>YNL670</td>
<td>MATa his3Δ11 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::NAT hda1Δ::KanMX</td>
<td>[304]</td>
</tr>
<tr>
<td>YNL676</td>
<td>MATa his3Δ11 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::NAT Hst3-9xMyc::KanMX</td>
<td>[304]</td>
</tr>
<tr>
<td>YNL678</td>
<td>MATa his3Δ11 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Hst1-9xMyc::KanMX</td>
<td>[304]</td>
</tr>
<tr>
<td>YNL681</td>
<td>MATa his3Δ11 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::NAT Hst1-9xMyc::KanMX</td>
<td>[304]</td>
</tr>
<tr>
<td>YNL685</td>
<td>MATa his3Δ11 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Hst2-9xMyc::KanMX</td>
<td>[304]</td>
</tr>
<tr>
<td>YNL687</td>
<td>MATa his3Δ11 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Sir2-9xMyc::KanMX</td>
<td>[304]</td>
</tr>
<tr>
<td>YNL689</td>
<td>MATa his3Δ11 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::NAT Sir2-9xMyc::KanMX</td>
<td>[304]</td>
</tr>
<tr>
<td>YNL698</td>
<td>MATa his3Δ11 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Hst3-9xMyc::KanMX</td>
<td>[304]</td>
</tr>
<tr>
<td>YNL700</td>
<td>MATa his3Δ11 leu2Δ0 met15Δ0 ura3Δ0 BY4741 tco89Δ::NAT Hst2-9xMyc::KanMX</td>
<td>[304]</td>
</tr>
<tr>
<td>YNL714</td>
<td>MATa his3Δ11 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Hst4-9xMyc::KanMX tco89Δ::NAT (MATED HAPLOIDS/SPORULATED)</td>
<td>[304]</td>
</tr>
<tr>
<td>YNL716</td>
<td>MATa his3Δ11 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Hst4-9xMyc::HYGRO sir4Δ::KanMX</td>
<td>[304]</td>
</tr>
</tbody>
</table>
Table A-1. (Continued).

<table>
<thead>
<tr>
<th>Strain</th>
<th>Genotype</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>YNL718</td>
<td>MATa his3Δ11 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Hst4-9xMyc::HYGRO sit4Δ::KANMX tco89Δ::HphNT1</td>
<td>[304]</td>
</tr>
<tr>
<td>YNL775</td>
<td>MATa his3Δ11 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Hst4-9xMyc::KANMX sap4Δ::HYGRO</td>
<td>[304]</td>
</tr>
<tr>
<td>YNL776</td>
<td>MATa his3Δ11 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Hst4-9xMyc::KANMX sap4Δ::HYGRO tco89Δ::NAT</td>
<td>[304]</td>
</tr>
<tr>
<td>YNL777</td>
<td>MATa his3Δ11 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Maf1-9xMyc::NAT sch9Δ KANMX</td>
<td>[304]</td>
</tr>
<tr>
<td>YNL778</td>
<td>MATa his3Δ11 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Maf1-9xMyc::NAT sap4Δ::HYGRO tco89Δ::NAT</td>
<td>[304]</td>
</tr>
<tr>
<td>YNL780</td>
<td>MATa his3Δ11 leu2Δ0 met15Δ0 ura3Δ0 BY4741 Maf1-9xMyc::NAT sap4Δ::HYGRO</td>
<td>[304]</td>
</tr>
<tr>
<td>YNL465</td>
<td>MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]-ura3Δ H3WT hmo1Δ::KanMX</td>
<td>This Study</td>
</tr>
<tr>
<td>YNL467</td>
<td>MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]-ura3Δ H3K37A hmo1Δ::KanMX</td>
<td>This Study</td>
</tr>
<tr>
<td>YNL490</td>
<td>MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]-ura3Δ H3WT nhp10Δ::KanMX</td>
<td>This Study</td>
</tr>
<tr>
<td>YNL491</td>
<td>MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]-ura3Δ H3K37A nhp10Δ::KanMX</td>
<td>This Study</td>
</tr>
<tr>
<td>YNL512</td>
<td>MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]-ura3Δ H3K37A nhp6Δ::KanMX</td>
<td>This Study</td>
</tr>
<tr>
<td>YNL514</td>
<td>MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]-ura3Δ H3WT nhp6Δ::KanMX</td>
<td>This Study</td>
</tr>
<tr>
<td>YNL595</td>
<td>MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]-ura3Δ H3K37A nhp6Δ::KanMX</td>
<td>This Study</td>
</tr>
<tr>
<td>YNL596</td>
<td>MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]-ura3Δ H3K37A nhp6Δ::KanMX</td>
<td>This Study</td>
</tr>
<tr>
<td>YNL653</td>
<td>MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]-ura3Δ H3WT NHP6A-EGFP::KanMX</td>
<td>This Study</td>
</tr>
<tr>
<td>YNL655</td>
<td>MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]-ura3Δ H3K37A sap4Δ::KanMX</td>
<td>This Study</td>
</tr>
<tr>
<td>YNL671</td>
<td>MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]-ura3Δ H3K37A hst4Δ::KanMX</td>
<td>This Study</td>
</tr>
<tr>
<td>YNL674</td>
<td>MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]-ura3Δ H3WT hst4Δ::KanMX</td>
<td>This Study</td>
</tr>
<tr>
<td>YNL710</td>
<td>MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]-ura3Δ H3K37A NHP6A-EGFP::KanMX</td>
<td>This Study</td>
</tr>
<tr>
<td>YNL722</td>
<td>MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]-ura3Δ H3WT NHP6A-yeGFP::HYGRO</td>
<td>This Study</td>
</tr>
<tr>
<td>Strain</td>
<td>Genotype</td>
<td>Source</td>
</tr>
<tr>
<td>---------</td>
<td>---------------------------------------------------------------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>YNL723</td>
<td>MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]-ura3Δ H3K37A NHP6A-yeGFP::HYGRO</td>
<td>This Study</td>
</tr>
<tr>
<td>YNL724</td>
<td>MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]-ura3Δ H3WT hst4Δ::KanMX NHP6A-yeGFP::HYGRO</td>
<td>This Study</td>
</tr>
<tr>
<td>YNL725</td>
<td>MATa his3Δ200 leu2Δ0 lys2Δ0 trp1Δ63 ura3Δ0met15Δ0 can1::MFA1pr-HIS3 hht1-hhf1::NatMX4 hht2-hhf2::[HHTS-HHFS]-ura3Δ H3K37A hst4Δ::KanMX NHP6A-yeGFP::HYGRO</td>
<td>This Study</td>
</tr>
</tbody>
</table>
Table A-2. List of plasmids used in the study.

<table>
<thead>
<tr>
<th>Parent</th>
<th>Vector/Insert</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>pHmo1</td>
<td>Gal-HA</td>
<td>Open Bio GAL1 collection</td>
</tr>
<tr>
<td>pNhp6A</td>
<td>Gal-HA</td>
<td>Open Bio GAL1 collection</td>
</tr>
<tr>
<td>pRS416</td>
<td>pSCH9-6xHA</td>
<td>[80]</td>
</tr>
<tr>
<td>pJU790</td>
<td>pSCH9-6xHA (T723A, S726A, T737A, S758A, S765A)</td>
<td>[80]</td>
</tr>
<tr>
<td>pJU855</td>
<td>pSCH9-6xHA (T723D, S726D, T737E, S758E, S765E)</td>
<td>[80]</td>
</tr>
<tr>
<td>pRS416</td>
<td>pSit4FL FLAG</td>
<td>This study</td>
</tr>
<tr>
<td>pRS416</td>
<td>pTco89 N-term Myc full-length</td>
<td>This study</td>
</tr>
<tr>
<td>pRS416</td>
<td>pTco89 C-term FLAG full-length</td>
<td>This study</td>
</tr>
<tr>
<td>pRS416</td>
<td>pTco89 C-term FLAG Frag A</td>
<td>This study</td>
</tr>
<tr>
<td>pRS416</td>
<td>pTco89 C-term FLAG Frag B</td>
<td>This study</td>
</tr>
<tr>
<td>pRS416</td>
<td>pTco89 C-term FLAG Frag C</td>
<td>This study</td>
</tr>
<tr>
<td>pRS416</td>
<td>pTco89 C-term FLAG Frag D</td>
<td>This study</td>
</tr>
<tr>
<td>pRS416</td>
<td>pTco89 C-term FLAG Frag E</td>
<td>This study</td>
</tr>
<tr>
<td>pRS416</td>
<td>pTco89 C-term FLAG Frag F</td>
<td>This study</td>
</tr>
</tbody>
</table>
Figure B-1. TORC1 inhibition over a range of rapamycin treatment conditions compared to a \textit{tco89Δ} mutant.

WT and \textit{tco89Δ} were grown to log phase and then mock treated, or treated with 25 nM or 300 nM rapamycin. Treatments shown represent resulting TORC1 activity following 20 and 60 minutes inhibition.
Figure B-2. Control experiments for Sch9^{2D3E} expression vectors.

A. *sch9Δ* cells were transformed with control vector (CV) or expression vectors containing various forms of Sch9 (see text for more details). Strains were grown in selective media to log phase and extracts were prepared and blotted to measure expression of mutant Sch9. G6PDH is included as an additional loading control. B. Strains from (A) were grown to stationary phase, five-fold serially diluted, and spotted onto selective media with a wide range of rapamycin concentrations. Plates with galactose and glycerol as the sole carbon sources are included as well. C. Wild-type Maf1-9xMyc and *sch9Δ* Maf1-9xMyc cells were transformed with the vectors from (A). Cells were grown to log phase, treated with 300 nM rapamycin for 60 min, and extracts were prepared. Samples were resolved on an 8% PAGE gel and blotted as shown. 

Figure B-3. Sirtuin relocalization in response to TORC1 inhibition.

A-E. WT or tco89Δ strains, containing 9XMyo epitope tagged sirtuins, were treated as indicated at log phase, fixed, permeabilized, and imaged by indirect immunofluorescence as described in the Chapter 2. Images are representative of at least three independent biological replicates, and are a subset of the quantification shown in Figure 3-16. DAPI staining denotes the nucleus and the green channel (FITC-conjugated secondary to α-Myc) tracks the localization of the sirtuins.
Figure B-3. Continued.
Figure B-3. Continued.
Figure B-4. Disruption of TORC1-responsive histone acetylation has no effect on H3K37A sensitivity to rapamycin.

A. H3WT, H3K37A, H3WT hst4Δ, H3K37 hst4Δ, H3WT sap4Δ and H3K37A sap4Δ were grown to log phase. Samples were mock treated or treated with rapamycin (25 nM or 300 nM) for 5.5 hours or 24 hours as indicated. Following treatment, pellets were washed with sterile water and spotted onto YPD plates as described in Chapter 2. B. Strains from (A) were grown to stationary phase and spotted onto YPD and YPD 10 nM Rap plates. C. H3WT and H3K37A cells were grown and spotted as in (B) to the plate media denoted. Photos are provided for rapidly growing strain/media combinations at 2 days, and at 6 days for the more sensitive pairings.
Figure B-5. Galactose-inducible HMGB expression vectors promote aberrant protein levels and distribution of Hmo1 and Nhp6A even prior to addition of galactose. H3WT cells were transformed with control vector, or galactose inducible expression vectors containing HA-tagged Hmo1 or Nhp6A. Strains were grown to log phase in synthetic complete raffinose media, and then mock treated or induced with 2% galactose for 20 minutes. Cells were fixed, processed by indirect immunofluorescence, and imaged by confocal microscopy, as described in Chapter 2. Images are representative of three independent experiments. DAPI staining denotes the nucleus and the green channel (FITC-conjugated secondary to α-HA) marks the localization of the HMGBs.
VITA

Jason John Workman was born in Grand Rapids, Michigan in 1987. He graduated from Bridgman High School in 2006, before attending Ferris State University in Big Rapids, MI. He received his Bachelor of Science degree in Biotechnology in 2010 and spent the following year working at The Dow Chemical Company in Midland, MI. In 2011, Jason enrolled in the University of Tennessee Health Science Center and spent the next five years in Dr. R Nicholas Laribee’s lab studying chromatin and epigenetics. Upon successful defense of the work described in this dissertation, Jason will be awarded a Doctor of Philosophy degree in Cancer and Developmental Biology.

Publications


